566P Survey of medical oncology status in Korea (SOMOS-K): A national survey of medical oncologists in the Korean Association for Clinical Oncology (KACO) (Englisch)
- Neue Suche nach: Kim, D. Y.
- Neue Suche nach: Lee, Y. G.
- Neue Suche nach: Kim, B. S.
- Neue Suche nach: Kim, D. Y.
- Neue Suche nach: Lee, Y. G.
- Neue Suche nach: Kim, B. S.
In:
ANNALS OF ONCOLOGY
;
27
;
N/A
;
2016
-
ISSN:
- Aufsatz (Zeitschrift) / Print
-
Titel:566P Survey of medical oncology status in Korea (SOMOS-K): A national survey of medical oncologists in the Korean Association for Clinical Oncology (KACO)
-
Beteiligte:
-
Erschienen in:ANNALS OF ONCOLOGY ; 27 ; N/A
-
Verlag:
- Neue Suche nach: OXFORD UNIVERSITY PRESS
-
Erscheinungsdatum:01.01.2016
-
Format / Umfang:N/A
-
ISSN:
-
Medientyp:Aufsatz (Zeitschrift)
-
Format:Print
-
Sprache:Englisch
- Neue Suche nach: 616.992
- Weitere Informationen zu Dewey Decimal Classification
-
Klassifikation:
DDC: 616.992 -
Datenquelle:
© Metadata Copyright the British Library Board and other contributors. All rights reserved.
Inhaltsverzeichnis – Band 27
Zeige alle Jahrgänge und Ausgaben
Die Inhaltsverzeichnisse werden automatisch erzeugt und basieren auf den im Index des TIB-Portals verfügbaren Einzelnachweisen der enthaltenen Beiträge. Die Anzeige der Inhaltsverzeichnisse kann daher unvollständig oder lückenhaft sein.
- 1
-
thanks to referees 2015| 2016
- 6
-
The influential and inspirational Gianni Bonadonna's life commitment to evidence-based cancer medicineCurigliano, G. / Valagussa, P. / Veronesi, U. / Gianni, L. et al. | 2016
- 8
-
Annals of oncology in 2015: the year in reviewSoria, J. C. et al. | 2016
- 10
-
Statistical controversies in clinical research: assessing pathologic complete response as a trial-level surrogate end point for early-stage breast cancerKorn, E. L. / Sachs, M. C. / McShane, L. M. et al. | 2016
- 16
-
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up†Colombo, N. / Creutzberg, C. / Amant, F. / Bosse, T. / González-Martín, A. / Ledermann, J. / Marth, C. / Nout, R. / Querleu, D. / Mirza, M. R. et al. | 2016
- 42
-
Prognostic impact and implications of extracapsular lymph node involvement in colorectal cancer: a systematic review with meta-analysisVeronese, N. / Nottegar, A. / Pea, A. / Solmi, M. / Stubbs, B. / Capelli, P. / Sergi, G. / Manzato, E. / Fassan, M. / Wood, L. D. et al. | 2016
- 49
-
Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysisRaggi, D. / Miceli, R. / Sonpavde, G. / Giannatempo, P. / Mariani, L. / Galsky, M. D. / Bellmunt, J. / Necchi, A. et al. | 2016
- 62
-
Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromesKomrokji, R. S. / List, A. F. et al. | 2016
- 68
-
Risk factors for neuroendocrine neoplasms: a systematic review and meta-analysisLeoncini, E. / Carioli, G. / La Vecchia, C. / Boccia, S. / Rindi, G. et al. | 2016
- 81
-
Fruits, vegetables and lung cancer risk: a systematic review and meta-analysisVieira, A. R. / Abar, L. / Vingeliene, S. / Chan, D. S. / Aune, D. / Navarro-Rosenblatt, D. / Stevens, C. / Greenwood, D. / Norat, T. et al. | 2016
- 96
-
Early market access of cancer drugs in the EUMartinalbo, J. / Bowen, D. / Camarero, J. / Chapelin, M. / Démolis, P. / Foggi, P. / Jonsson, B. / Llinares, J. / Moreau, A. / O'Connor, D. et al. | 2016
- 106
-
Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer†O'Shaughnessy, J. / Campone, M. / Brain, E. / Neven, P. / Hayes, D. / Bondarenko, I. / Griffin, T. W. / Martin, J. / De Porre, P. / Kheoh, T. et al. | 2016
- 114
-
Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study†Tewari, K. S. / Java, J. J. / Eskander, R. N. / Monk, B. J. / Burger, R. A. et al. | 2016
- 121
-
Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001–02)†Aparicio, T. / Lavau-Denes, S. / Phelip, J. M. / Maillard, E. / Jouve, J. L. / Gargot, D. / Gasmi, M. / Locher, C. / Adhoute, X. / Michel, P. et al. | 2016
- 127
-
Comprehensive analyses using next-generation sequencing and immunohistochemistry enable precise treatment in advanced gastric cancerKuboki, Y. / Yamashita, S. / Niwa, T. / Ushijima, T. / Nagatsuma, A. / Kuwata, T. / Yoshino, T. / Doi, T. / Ochiai, A. / Ohtsu, A. et al. | 2016
- 134
-
Prognostic factors for progression-free and overall survival in advanced biliary tract cancerBridgewater, J. / Lopes, A. / Wasan, H. / Malka, D. / Jensen, L. / Okusaka, T. / Knox, J. / Wagner, D. / Cunningham, D. / Shannon, J. et al. | 2016
- 140
-
A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trialHagman, H. / Frödin, J. E. / Berglund, . / Sundberg, J. / Vestermark, L. W. / Albertsson, M. / Fernebro, E. / Johnsson, A. et al. | 2016
- 147
-
Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategiesIlie, M. / Long-Mira, E. / Bence, C. / Butori, C. / Lassalle, S. / Bouhlel, L. / Fazzalari, L. / Zahaf, K. / Lalvée, S. / Washetine, K. et al. | 2016
- 154
-
A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers†Li, B. T. / Drilon, A. / Johnson, M. L. / Hsu, M. / Sima, C. S. / McGinn, C. / Sugita, H. / Kris, M. G. / Azzoli, C. G. et al. | 2016
- 159
-
Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registryWagstaff, J. / Jones, R. / Hawkins, R. / Porfiri, E. / Pickering, L. / Bahl, A. / Brown, J. / Buchan, S. et al. | 2016
- 165
-
Comprehensive serum cytokine analysis identifies IL-1RA and soluble IL-2Rα as predictors of event-free survival in T-cell lymphomaGupta, M. / Stenson, M. / O'Byrne, M. / Maurer, M. J. / Habermann, T. / Cerhan, J. R. / Weiner, G. W. / Witzig, T. E. et al. | 2016
- 172
-
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial†Weinstein, C. / Jordan, K. / Green, S. A. / Camacho, E. / Khanani, S. / Beckford-Brathwaite, E. / Vallejos, W. / Liang, L. W. / Noga, S. J. / Rapoport, B. L. et al. | 2016
- 178
-
Metabolic phenotyping of human blood plasma: a powerful tool to discriminate between cancer types?Louis, E. / Adriaensens, P. / Guedens, W. / Vanhove, K. / Vandeurzen, K. / Darquennes, K. / Vansteenkiste, J. / Dooms, C. / de Jonge, E. / Thomeer, M. et al. | 2016
- 185
-
Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study)Takeuchi, K. / Togashi, Y. / Kamihara, Y. / Fukuyama, T. / Yoshioka, H. / Inoue, A. / Katsuki, H. / Kiura, K. / Nakagawa, K. / Seto, T. et al. | 2016
- 192
-
The reporting of adverse events in oncology phase III trials: a comparison of the current status versus the expectations of the EORTC membersMaillet, D. / Blay, J. Y. / You, B. / Rachdi, A. / Gan, H. K. / Péron, J. et al. | 2016
- 199
-
A clinical case of invasive lobular breast carcinoma with ERBB2 and CDH1 mutations presenting a dramatic response to anti-HER2-directed therapyGrellety, T. / Soubeyran, I. / Robert, J. / Bonnefoi, H. / Italiano, A. et al. | 2016
- 200
-
Two cases of EGFR mutation-positive lung adenocarcinoma that transformed into squamous cell carcinoma: successful treatment of one case with rociletinibHaratani, K. / Hayashi, H. / Watanabe, S. / Kaneda, H. / Yoshida, T. / Takeda, M. / Shimizu, T. / Nakagawa, K. et al. | 2016
- 202
-
More on sunitinib 2 weeks on/1 week off schedule: the Rainbow analysisBasso, U. / Maruzzo, M. et al. | 2016
- 202
-
A rational approach for salvage of testicular cancer patientsSelle, F. / Soares, D. G. / Lotz, J. P. et al. | 2016
- 203
-
Reply to the letter to the editor ‘The ESMO Magnitude of Clinical Benefit Scaling Tool: from theory to practice’ by Hartmann and the letter ‘Comment on ESMO Magnitude of Clinical Benefit Scale’ by Muhonen et al.Cherny, N. I. / Sullivan, R. / Dafni, U. / Kerst, J. M. / Sobrero, A. / Zielinski, C. / de Vries, E. G. / Piccart, M. J. et al. | 2016
- 205
-
How much evidence isn't in evidence-based guidelines?Johnson, M. J. / Currow, D. C. et al. | 2016
- 206
-
Enzalutamide and sleep apnea: an emerging central nervous system side-effect?Labrize, F. / Cany, L. / Massard, C. / Loriot, Y. / Sargos, P. / Gross-Goupil, M. / Roubaud, G. et al. | 2016
- 206
-
PD-L1 copy number gain in nonsmall-cell lung cancer defines a new subset of patients for anti PD-L1 therapyGoldmann, T. / Kugler, C. / Reinmuth, N. / Vollmer, E. / Reck, M. et al. | 2016
- 208
-
Vitamin D and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Case–Control ConsortiumWaterhouse, M. / Risch, H. A. / Bosetti, C. / Anderson, K. E. / Petersen, G. M. / Bamlet, W. R. / Cotterchio, M. / Cleary, S. P. / Ibiebele, T. I. / La Vecchia, C. et al. | 2016
- 209
-
Planning and reporting of quality-of-life outcomes in cancer trialsSchandelmaier, S. / Conen, K. / von Elm, E. / You, J. J. / Blümle, A. / Tomonaga, Y. / Saccilotto, R. / Amstutz, A. / Bengough, T. / Meerpohl, J. J. et al. | 2016
- 211
-
Environmental emissions, public health and lung cancer riskSwanton, C. / Boffetta, P. / Peston, R. / Soria, J. C. et al. | 2016
- 212
-
Guidelines for endometrial cancer management: finding order amid the uncertaintiesEifel, P. J. et al. | 2016
- 214
-
Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodiesPostel-Vinay, S. / Aspeslagh, S. / Lanoy, E. / Robert, C. / Soria, J. C. / Marabelle, A. et al. | 2016
- 225
-
Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancerDonnem, T. / Kilvaer, T. K. / Andersen, S. / Richardsen, E. / Paulsen, E. E. / Hald, S. M. / Al-Saad, S. / Brustugun, O. T. / Helland, A. / Lund-Iversen, M. et al. | 2016
- 233
-
Waldenström's macroglobulinemia: a clinical perspective in the era of novel therapeuticsDimopoulos, M. A. / Kastritis, E. / Ghobrial, I. M. et al. | 2016
- 240
-
Beyond the exome: the role of non-coding somatic mutations in cancerPiraino, S. W. / Furney, S. J. et al. | 2016
- 249
-
Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancerPruneri, G. / Vingiani, A. / Bagnardi, V. / Rotmensz, N. / De Rose, A. / Palazzo, A. / Colleoni, A. M. / Goldhirsch, A. / Viale, G. et al. | 2016
- 256
-
In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer ConsortiumLobbezoo, D. J. / van Kampen, R. J. / Voogd, A. C. / Dercksen, M. W. / van den Berkmortel, F. / Smilde, T. J. / van de Wouw, A. J. / Peters, F. P. / van Riel, J. M. / Peters, N. A. et al. | 2016
- 257
-
Can ovarian suppression with gonadotropin-releasing hormone analogs (GnRHa) preserve fertility in cancer patients?Rodriguez-Wallberg, K. / Turan, V. / Munster, P. / Oktay, K. et al. | 2016
- 262
-
Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer†Mitsuhashi, A. / Sato, Y. / Kiyokawa, T. / Koshizaka, M. / Hanaoka, H. / Shozu, M. et al. | 2016
- 267
-
Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIVLévi, F. A. / Boige, V. / Hebbar, M. / Smith, D. / Lepère, C. / Focan, C. / Karaboué, A. / Guimbaud, R. / Carvalho, C. / Tumolo, S. et al. | 2016
- 274
-
A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinomaRosati, G. / Ambrosini, G. / Barni, S. / Andreoni, B. / Corradini, G. / Luchena, G. / Daniele, B. / Gaion, F. / Oliverio, G. / Duro, M. et al. | 2016
- 281
-
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohortMazières, J. / Barlesi, F. / Filleron, T. / Besse, B. / Monnet, I. / Beau-Faller, M. / Peters, S. / Dansin, E. / Früh, M. / Pless, M. et al. | 2016
- 286
-
Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAILGraff, J. N. / Baciarello, G. / Armstrong, A. J. / Higano, C. S. / Iversen, P. / Flaig, T. W. / Forer, D. / Parli, T. / Phung, D. / Tombal, B. et al. | 2016
- 294
-
Pre-treatment lymphocytopaenia is an adverse prognostic biomarker in muscle-invasive and advanced bladder cancer†Joseph, N. / Dovedi, S. J. / Thompson, C. / Lyons, J. / Kennedy, J. / Elliott, T. / West, C. M. / Choudhury, A. et al. | 2016
- 300
-
Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumorsCierna, Z. / Mego, M. / Miskovska, V. / Machalekova, K. / Chovanec, M. / Svetlovska, D. / Hainova, K. / Rejlekova, K. / Macak, D. / Spanik, S. et al. | 2016
- 306
-
Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomesLaurent, C. / Delas, A. / Gaulard, P. / Haioun, C. / Moreau, A. / Xerri, L. / Traverse-Glehen, A. / Rousset, T. / Quintin-Roue, I. / Petrella, T. et al. | 2016
- 314
-
Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single-center studyLassalle, A. / Thomaré, P. / Fronteau, C. / Mahé, B. / Jubé, C. / Blin, N. / Voldoire, M. / Dubruille, V. / Tessoulin, B. / Touzeau, C. et al. | 2016
- 318
-
Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumorsWong, S. J. / Karrison, T. / Hayes, D. N. / Kies, M. S. / Cullen, K. J. / Tanvetyanon, T. / Argiris, A. / Takebe, N. / Lim, D. / Saba, N. F. et al. | 2016
- 324
-
The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MOSAIC, a multicenter cluster-randomized phase III study (SAKK 95/06)Strasser, F. / Blum, D. / von Moos, R. / Cathomas, R. / Ribi, K. / Aebi, S. / Betticher, D. / Hayoz, S. / Klingbiel, D. / Brauchli, P. et al. | 2016
- 332
-
Next-generation sequencing of the basal cell carcinoma miRNome and a description of novel microRNA candidates under neoadjuvant vismodegib therapy: an integrative molecular and surgical case studySand, M. / Bechara, F. G. / Gambichler, T. / Sand, D. / Friedländer, M. R. / Bromba, M. / Schnabel, R. / Hessam, S. et al. | 2016
- 339
-
Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance)†Yoon, H. H. / Foster, N. R. / Meyers, J. P. / Steen, P. D. / Visscher, D. W. / Pillai, R. / Prow, D. M. / Reynolds, C. M. / Marchello, B. T. / Mowat, R. B. et al. | 2016
- 344
-
Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: what is the added value of whole exome sequencing?Postel-Vinay, S. / Boursin, Y. / Massard, C. / Hollebecque, A. / Ileana, E. / Chiron, M. / Jung, J. / Lee, J. S. / Balogh, Z. / Adam, J. et al. | 2016
- 353
-
Access to innovative oncology medicines in EuropeBergmann, L. / Enzmann, H. / Thirstrup, S. / Schweim, J. K. / Widera, I. / Zwierzina, H. et al. | 2016
- 358
-
Prevalence of rare EGFR gene mutations in nonsmall-cell lung cancer: a multicenter study on 3856 Polish Caucasian patientsKrawczyk, P. / Reszka, K. / Ramlau, R. / Powrózek, T. / Pankowski, J. / Wojas-Krawczyk, K. / Kalinka-Warzocha, E. / Szczęsna, A. / Nicoś, M. / Jarosz, B. et al. | 2016
- 359
-
Reply to the letter to the editor ‘Prevalence of rare EGFR mutations in non-small cell lung cancer: a multicenter study on 3856 Polish Caucasian patients’ by Krawczyk et al.Beau-Faller, M. / Cadranel, J. et al. | 2016
- 360
-
KRT81 miR-SNP rs3660 is associated with risk and survival of NSCLCRobles, A. I. / Ryan, B. M. et al. | 2016
- 361
-
Reply to the letter to the editor ‘KRT81 miR-SNP rs3660 is associated with risk and survival of NSCLC’ by Robles et al.Lee, S. Y. / Choi, J. E. / Park, J. Y. et al. | 2016
- 363
-
Reply to ‘Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance’ by Funck-Brentano et al.Goldwirt, L. / Chami, I. / Feugeas, J. P. / Pages, C. / Brunet-Possenti, F. / Allayous, C. / Baroudjian, B. / Madelaine, I. / Sauvageon, H. / Mourah, S. et al. | 2016
- 363
-
More colors to the paletteBracarda, S. et al. | 2016
- 364
-
Reply to the letter to the editor ‘Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumor response and tolerance’ by Funck-Brentano et al.Funck-Brentano, E. / Alvarez, J. C. / Longvert, C. / Abe, E. / Beauchet, A. / Saiag, P. / Funck-Brentano, C. et al. | 2016
- 366
-
Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysisBracarda, S. / Iacovelli, R. / Boni, L. / Rizzo, M. / Derosa, L. / Rossi, M. / Galli, L. / Procopio, G. / Sisani, M. / Longo, F. et al. | 2016
- 367
-
Being molecular in the molecular ageRaghupathy, R. / Mok, T. et al. | 2016
- 369
-
Personalized testing based on polygenic risk score is promising for more efficient population-based screening programs for common oncological diseasesRadice, P. / Pharoah, P. D. / Peterlongo, P. et al. | 2016
- 371
-
Stereotactic radiation and checkpoint inhibitors in melanoma patients with BM: a question of drug, timing or both?Dhermain, F. / Deutsch, E. et al. | 2016
- 373
-
Statistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agentsSaad, E. D. / Buyse, M. et al. | 2016
- 379
-
Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European PanelHadji, P. / Coleman, R. E. / Wilson, C. / Powles, T. J. / Clézardin, P. / Aapro, M. / Costa, L. / Body, J. J. / Markopoulos, C. / Santini, D. et al. | 2016
- 390
-
Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysisFleury, I. / Chevret, S. / Pfreundschuh, M. / Salles, G. / Coiffier, B. / van Oers, M. H. / Gisselbrecht, C. / Zucca, E. / Herold, M. / Ghielmini, M. et al. | 2016
- 397
-
Non-AIDS-related malignancies: expert consensus review and practical applications from the multidisciplinary CANCERVIH Working GroupSpano, J. P. / Poizot-Martin, I. / Costagliola, D. / Boué, F. / Rosmorduc, O. / Lavolé, A. / Choquet, S. / Heudel, P. E. / Leblond, V. / Gabarre, J. et al. | 2016
- 409
-
Regulation of PD-L1: a novel role of pro-survival signalling in cancerChen, J. / Jiang, C. C. / Jin, L. / Zhang, X. D. et al. | 2016
- 417
-
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trialSchuler, M. / Yang, J. C. / Park, K. / Kim, J. H. / Bennouna, J. / Chen, Y. M. / Chouaid, C. / De Marinis, F. / Feng, J. F. / Grossi, F. et al. | 2016
- 423
-
Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trialsRamalingam, S. S. / O'Byrne, K. / Boyer, M. / Mok, T. / Jänne, P. A. / Zhang, H. / Liang, J. / Taylor, I. / Sbar, E. I. / Paz-Ares, L. et al. | 2016
- 429
-
Implications of polygenic risk for personalised colorectal cancer screeningFrampton, M. J. / Law, P. / Litchfield, K. / Morris, E. J. / Kerr, D. / Turnbull, C. / Tomlinson, I. P. / Houlston, R. S. et al. | 2016
- 434
-
Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapyAhmed, K. A. / Stallworth, D. G. / Kim, Y. / Johnstone, P. A. / Harrison, L. B. / Caudell, J. J. / Yu, H. H. / Etame, A. B. / Weber, J. S. / Gibney, G. T. et al. | 2016
- 441
-
Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4)†Motzer, R. J. / Alyasova, A. / Ye, D. / Karpenko, A. / Li, H. / Alekseev, B. / Xie, L. / Kurteva, G. / Kowalyszyn, R. / Karyakin, O. et al. | 2016
- 449
-
Vinflunine–gemcitabine versus vinflunine–carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1)†De Santis, M. / Wiechno, P. J. / Bellmunt, J. / Lucas, C. / Su, W. C. / Albiges, L. / Lin, C. C. / Senkus-Konefka, E. / Flechon, A. / Mourey, L. et al. | 2016
- 454
-
A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxelChi, K. N. / Kheoh, T. / Ryan, C. J. / Molina, A. / Bellmunt, J. / Vogelzang, N. J. / Rathkopf, D. E. / Fizazi, K. / Kantoff, P. W. / Li, J. et al. | 2016
- 460
-
Association between PSA kinetics and cancer-specific mortality in patients with localised prostate cancer: analysis of the placebo arm of the SPCG-6 studyThomsen, F. B. / Brasso, K. / Berg, K. D. / Gerds, T. A. / Johansson, J. E. / Angelsen, A. / Tammela, T. L. / Iversen, P. et al. | 2016
- 467
-
Genetic testing in a cohort of young patients with HER2-amplified breast cancerEccles, D. M. / Li, N. / Handwerker, R. / Maishman, T. / Copson, E. R. / Durcan, L. T. / Gerty, S. M. / Jones, L. / Evans, D. G. / Haywood, L. et al. | 2016
- 474
-
Concurrent or sequential letrozole with adjuvant breast radiotherapy: final results of the CO-HO-RT phase II randomized trial†Bourgier, C. / Kerns, S. / Gourgou, S. / Lemanski, C. / Gutowski, M. / Fenoglietto, P. / Romieu, G. / Crompton, N. / Lacombe, J. / Pèlegrin, A. et al. | 2016
- 480
-
Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21 755 patients from the Japanese breast cancer registryNiikura, N. / Tomotaki, A. / Miyata, H. / Iwamoto, T. / Kawai, M. / Anan, K. / Hayashi, N. / Aogi, K. / Ishida, T. / Masuoka, H. et al. | 2016
- 487
-
Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trialLorusso, D. / Scambia, G. / Pignata, S. / Sorio, R. / Amadio, G. / Lepori, S. / Mosconi, A. / Pisano, C. / Mangili, G. / Maltese, G. et al. | 2016
- 494
-
Prognostic value of tumor-infiltrating lymphocytes in Epstein–Barr virus-associated gastric cancerKang, B. W. / Seo, A. N. / Yoon, S. / Bae, H. I. / Jeon, S. W. / Kwon, O. K. / Chung, H. Y. / Yu, W. / Kang, H. / Kim, J. G. et al. | 2016
- 502
-
A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer†Ueno, M. / Okusaka, T. / Omuro, Y. / Isayama, H. / Fukutomi, A. / Ikeda, M. / Mizuno, N. / Fukuzawa, K. / Furukawa, M. / Iguchi, H. et al. | 2016
- 508
-
Epstein–Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsinKim, S. J. / Kim, J. H. / Ki, C. S. / Ko, Y. H. / Kim, J. S. / Kim, W. S. et al. | 2016
- 513
-
Is it possible to encourage hope in non-advanced cancer patients? We must tryRipamonti, C. I. / Miccinesi, G. / Pessi, M. A. / Di Pede, P. / Ferrari, M. et al. | 2016
- 519
-
Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacyRugo, H. S. / Hortobagyi, G. N. / Yao, J. / Pavel, M. / Ravaud, A. / Franz, D. / Ringeisen, F. / Gallo, J. / Rouyrre, N. / Anak, O. et al. | 2016
- 526
-
A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumorsTolcher, A. W. / Papadopoulos, K. P. / Patnaik, A. / Wilson, K. / Thayer, S. / Zanghi, J. / Gemo, A. T. / Kavanaugh, W. M. / Keer, H. N. / LoRusso, P. M. et al. | 2016
- 532
-
Methanol-based fixation is superior to buffered formalin for next-generation sequencing of DNA from clinical cancer samplesPiskorz, A. M. / Ennis, D. / Macintyre, G. / Goranova, T. E. / Eldridge, M. / Segui-Gracia, N. / Valganon, M. / Hoyle, A. / Orange, C. / Moore, L. et al. | 2016
- 539
-
TP53 mutational status is predictive of pazopanib response in advanced sarcomasKoehler, K. / Liebner, D. / Chen, J. L. et al. | 2016
- 544
-
Successful treatment with an anti-PD-1 antibody for progressing brain metastases in renal cell cancerRothermundt, C. / Hader, C. / Gillessen, S. et al. | 2016
- 545
-
Many men with castrate-sensitive metastatic prostate cancer should not receive chemotherapyTannock, I. F. / Sternberg, C. N. et al. | 2016
- 546
-
Idiopathic thrombocytopenic purpura induced by nivolumab in a metastatic melanoma patient with elevated PD-1 expression on B cellsKanameishi, S. / Otsuka, A. / Nonomura, Y. / Fujisawa, A. / Endo, Y. / Kabashima, K. et al. | 2016
- 548
-
Reply to the letter to the editor ‘Can ovarian suppression with gonadotropin releasing hormone analogs (GnRHa) preserve fertility in cancer patients?’ by Rodriguez-Wallberg et al.Lambertini, M. / Peccatori, F. A. / Moore, H. C. / Del Mastro, L. et al. | 2016
- 549
-
Reply to the letter to the editor ‘Integration between oncology and palliative care: does one size fit all?’ by Verna et al.Hui, D. / Bansal, S. / Strasser, F. / Morita, T. / Caraceni, A. / Davis, M. / Cherny, N. / Kaasa, S. / Currow, D. / Abernethy, A. et al. | 2016
- 549
-
Integration between oncology and palliative care: does one size fit all?Verna, L. / Giusti, R. / Marchetti, P. / Ficorella, C. / Porzio, G. et al. | 2016
- 550
-
Reply to the letter to the editor ‘How much evidence isn't in evidence-based guidelines?’ by Johnson et al.Cherny, N. I. / Kloke, M. / Cervantes, A. / Pentheroudakis, G. et al. | 2016
- 551
-
Trabectedin is an effective second-line treatment in soft tissue sarcoma patientsPeugniez, C. / Cousin, S. / Penel, N. et al. | 2016
- 553
-
Medication to reduce breast cancer risk: why is uptake low?Butow, P. / Phillips, K. A. et al. | 2016
- 555
-
HER2 imaging in the ZEPHIR studyClark, A. S. / DeMichele, A. / Mankoff, D. et al. | 2016
- 557
-
Another surprising role for exosomes? Improving next-generation sequencing-based cancer diagnostics in liquid biopsiesSzallasi, Z. et al. | 2016
- 559
-
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paperChampiat, S. / Lambotte, O. / Barreau, E. / Belkhir, R. / Berdelou, A. / Carbonnel, F. / Cauquil, C. / Chanson, P. / Collins, M. / Durrbach, A. et al. | 2016
- 575
-
Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysisSmith, S. G. / Sestak, I. / Forster, A. / Partridge, A. / Side, L. / Wolf, M. S. / Horne, R. / Wardle, J. / Cuzick, J. et al. | 2016
- 590
-
Pathways to improving combined modality therapy for stage III nonsmall-cell lung cancerSchild, S. E. / Vokes, E. E. et al. | 2016
- 599
-
IDH mutations in cancer and progress toward development of targeted therapeuticsDang, L. / Yen, K. / Attar, E. C. et al. | 2016
- 608
-
Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysisTruong, J. / Lee, E. K. / Trudeau, M. E. / Chan, K. K. et al. | 2016
- 619
-
Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trialGebhart, G. / Lamberts, L. E. / Wimana, Z. / Garcia, C. / Emonts, P. / Ameye, L. / Stroobants, S. / Huizing, M. / Aftimos, P. / Tol, J. et al. | 2016
- 625
-
Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsiesPetrillo, M. / Zannoni, G. F. / Beltrame, L. / Martinelli, E. / DiFeo, A. / Paracchini, L. / Craparotta, I. / Mannarino, L. / Vizzielli, G. / Scambia, G. et al. | 2016
- 635
-
Minimally invasive genomic and transcriptomic profiling of visceral cancers by next-generation sequencing of circulating exosomesSan Lucas, F. A. / Allenson, K. / Bernard, V. / Castillo, J. / Kim, D. U. / Ellis, K. / Ehli, E. A. / Davies, G. E. / Petersen, J. L. / Li, D. et al. | 2016
- 642
-
Clinical correlation of extensive-stage small-cell lung cancer genomicsDowlati, A. / Lipka, M. B. / McColl, K. / Dabir, S. / Behtaj, M. / Kresak, A. / Miron, A. / Yang, M. / Sharma, N. / Fu, P. et al. | 2016
- 648
-
Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas†Ramanathan, R. K. / Goldstein, D. / Korn, R. L. / Arena, F. / Moore, M. / Siena, S. / Teixeira, L. / Tabernero, J. / Van Laethem, J. L. / Liu, H. et al. | 2016
- 654
-
CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancerChiorean, E. G. / Von Hoff, D. D. / Reni, M. / Arena, F. P. / Infante, J. R. / Bathini, V. G. / Wood, T. E. / Mainwaring, P. N. / Muldoon, R. T. / Clingan, P. R. et al. | 2016
- 660
-
A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junctionKlevebro, F. / Alexandersson von Döbeln, G. / Wang, N. / Johnsen, G. / Jacobsen, A. B. / Friesland, S. / Hatlevoll, I. / Glenjen, N. I. / Lind, P. / Tsai, J. A. et al. | 2016
- 668
-
Preoperative versus postoperative docetaxel–cisplatin–fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial†Fazio, N. / Biffi, R. / Maibach, R. / Hayoz, S. / Thierstein, S. / Brauchli, P. / Bernhard, J. / Stupp, R. / Andreoni, B. / Renne, G. et al. | 2016
- 673
-
Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma†Al-Batran, S. E. / Van Cutsem, E. / Oh, S. C. / Bodoky, G. / Shimada, Y. / Hironaka, S. / Sugimoto, N. / Lipatov, O. N. / Kim, T. Y. / Cunningham, D. et al. | 2016
- 680
-
A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinomaCiuleanu, T. / Bazin, I. / Lungulescu, D. / Miron, L. / Bondarenko, I. / Deptala, A. / Rodriguez-Torres, M. / Giantonio, B. / Fox, N. L. / Wissel, P. et al. | 2016
- 687
-
Prognostic value of neutrophil-to-lymphocyte ratio in advanced oesophago-gastric cancer: exploratory analysis of the REAL-2 trialGrenader, T. / Waddell, T. / Peckitt, C. / Oates, J. / Starling, N. / Cunningham, D. / Bridgewater, J. et al. | 2016
- 693
-
Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer†Carter, C. A. / Rajan, A. / Keen, C. / Szabo, E. / Khozin, S. / Thomas, A. / Brzezniak, C. / Guha, U. / Doyle, L. A. / Steinberg, S. M. et al. | 2016
- 699
-
Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trialsFizazi, K. / Flaig, T. W. / Stöckle, M. / Scher, H. I. / de Bono, J. S. / Rathkopf, D. E. / Ryan, C. J. / Kheoh, T. / Li, J. / Todd, M. B. et al. | 2016
- 706
-
Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO studyPérez-Valderrama, B. / Arranz Arija, J. A. / Rodríguez Sánchez, A. / Pinto Marín, A. / Borrega García, P. / Castellano Gaunas, D. E. / Rubio Romero, G. / Maximiano Alonso, C. / Villa Guzmán, J. C. / Puertas Álvarez, J. L. et al. | 2016
- 712
-
A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomasKim, S. J. / Shin, D. Y. / Kim, J. S. / Yoon, D. H. / Lee, W. S. / Lee, H. / Do, Y. R. / Kang, H. J. / Eom, H. S. / Ko, Y. H. et al. | 2016
- 719
-
Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL)†Cottereau, A. S. / Becker, S. / Broussais, F. / Casasnovas, O. / Kanoun, S. / Roques, M. / Charrier, N. / Bertrand, S. / Delarue, R. / Bonnet, C. et al. | 2016
- 725
-
European cancer mortality predictions for the year 2016 with focus on leukaemiasMalvezzi, M. / Carioli, G. / Bertuccio, P. / Rosso, T. / Boffetta, P. / Levi, F. / La Vecchia, C. / Negri, E. et al. | 2016
- 732
-
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumabFerrucci, P. F. / Ascierto, P. A. / Pigozzo, J. / Del Vecchio, M. / Maio, M. / Antonini Cappellini, G. C. / Guidoboni, M. / Queirolo, P. / Savoia, P. / Mandalà, M. et al. | 2016
- 738
-
Whole-exome sequencing in osteosarcoma reveals important heterogeneity of genetic alterationsBousquet, M. / Noirot, C. / Accadbled, F. / Sales de Gauzy, J. / Castex, M. P. / Brousset, P. / Gomez-Brouchet, A. et al. | 2016
- 745
-
The GILDA trial finds no survival benefit from intensified screening after primary resection of colorectal cancer: the PulMiCC trial tests the survival benefit of pulmonary metastasectomy for detected asymptomatic lung metastasesTreasure, T. / Macbeth, F. et al. | 2016
- 746
-
Serum neuron-specific enolase level is an independent predictor of overall survival in patients with gastroenteropancreatic neuroendocrine tumorsvan Adrichem, R. C. / Kamp, K. / Vandamme, T. / Peeters, M. / Feelders, R. A. / de Herder, W. W. et al. | 2016
- 747
-
Number needed to treat for pricing costly anticancer drugs: the example of regorafenib in metastatic colorectal cancerGraziano, F. / Rulli, E. / Biagioli, E. / Catalano, V. et al. | 2016
- 748
-
Genome sequencing for nonsmall-cell lung cancer identifies a basis for nintedanib sensitivity†Takeda, M. / Sakai, K. / Okamoto, K. / Hayashi, H. / Tanaka, K. / Shimizu, T. / Nishio, K. / Nakagawa, K. et al. | 2016
- 750
-
Reply to the letter to the editor ‘Many men with castrate-sensitive metastatic prostate cancer should not receive chemotherapy’ by Tannock et al.Parker, C. / Gillessen, S. / Heidenreich, A. / Horwich, A. et al. | 2016
- 751
-
Survival in young adults diagnosed with follicular lymphomaCalvo, V. / Provencio, M. / Gómez Codina, J. / Rodríguez Abreu, D. / Rueda, A. et al. | 2016
- 752
-
Drug–drug interactions associated with kinase inhibitors: highlighting a new resource for oncologists and clinical pharmacistsGelderblom, H. / Köhne, C. H. / Launay-Vacher, V. / van Leeuwen, R. W. et al. | 2016
- 753
-
Survival after resection of perihilar cholangiocarcinoma—development and external validation of a prognostic nomogramGroot Koerkamp, B. / Wiggers, J. K. / Gonen, M. / Doussot, A. / Allen, P. J. / Besselink, M. G. / Blumgart, L. H. / Busch, O. R. / D'Angelica, M. I. / DeMatteo, R. P. et al. | 2016
- 755
-
PARP inhibitor receives FDA breakthrough therapy designation in castration resistant prostate cancer: beyond germline BRCA mutationsHelleday, T. et al. | 2016
- 758
-
Reporting incidental germline variants in the context of day-to-day somatic genomic profilingMak, G. / Moschetta, M. / Arkenau, H. T. et al. | 2016
- 760
-
Statistical controversies in clinical research: statistical significance—too much of a good thing …Buyse, M. / Hurvitz, S. A. / Andre, F. / Jiang, Z. / Burris, H. A. / Toi, M. / Eiermann, W. / Lindsay, M. A. / Slamon, D. et al. | 2016
- 763
-
Molecular classification of gastric cancerChia, N. Y. / Tan, P. et al. | 2016
- 770
-
New drugs in acute myeloid leukemiaKadia, T. M. / Ravandi, F. / Cortes, J. / Kantarjian, H. et al. | 2016
- 778
-
Breakthrough therapies in B-cell non-Hodgkin lymphomaCheah, C. Y. / Fowler, N. H. / Wang, M. L. et al. | 2016
- 787
-
Phosphoproteomics in translational research: a sarcoma perspectiveNoujaim, J. / Payne, L. S. / Judson, I. / Jones, R. L. / Huang, P. H. et al. | 2016
- 795
-
Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocolMeric-Bernstam, F. / Brusco, L. / Daniels, M. / Wathoo, C. / Bailey, A. M. / Strong, L. / Shaw, K. / Lu, K. / Qi, Y. / Zhao, H. et al. | 2016
- 801
-
Response to angiotensin blockade with irbesartan in a patient with metastatic colorectal cancerJones, M. R. / Schrader, K. A. / Shen, Y. / Pleasance, E. / Ch'ng, C. / Dar, N. / Yip, S. / Renouf, D. J. / Schein, J. E. / Mungall, A. J. et al. | 2016
- 806
-
Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial†Zdenkowski, N. / Forbes, J. F. / Boyle, F. M. / Kannourakis, G. / Gill, P. G. / Bayliss, E. / Saunders, C. / Della-Fiorentina, S. / Kling, N. / Campbell, I. et al. | 2016
- 812
-
A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)Bonnefoi, H. / Grellety, T. / Tredan, O. / Saghatchian, M. / Dalenc, F. / Mailliez, A. / L'Haridon, T. / Cottu, P. / Abadie-Lacourtoisie, S. / You, B. et al. | 2016
- 818
-
The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer: a National Cancer Database (NCDB) analysisRusthoven, C. G. / Rabinovitch, R. A. / Jones, B. L. / Koshy, M. / Amini, A. / Yeh, N. / Jackson, M. W. / Fisher, C. M. et al. | 2016
- 828
-
Identifying the potential long-term survivors among breast cancer patients with distant metastasisLee, E. S. / Jung, S. Y. / Kim, J. Y. / Kim, J. J. / Yoo, T. K. / Kim, Y. G. / Lee, K. S. / Kim, E. K. / Min, J. W. et al. | 2016
- 834
-
Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III studyBujko, K. / Wyrwicz, L. / Rutkowski, A. / Malinowska, M. / Pietrzak, L. / Kryński, J. / Michalski, W. / Olędzki, J. / Kuśnierz, J. / Zając, L. et al. | 2016
- 843
-
FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trialsCremolini, C. / Loupakis, F. / Masi, G. / Lonardi, S. / Granetto, C. / Mancini, M. L. / Chiara, S. / Moretto, R. / Rossini, D. / Vitello, S. et al. | 2016
- 850
-
Role of major resection in pulmonary metastasectomy for colorectal cancer in the Spanish prospective multicenter study (GECMP-CCR)Hernández, J. / Molins, L. / Fibla, J. J. / Heras, F. / Embún, R. / Rivas, J. J. et al. | 2016
- 856
-
Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29)†Koeberle, D. / Dufour, J. F. / Demeter, G. / Li, Q. / Ribi, K. / Samaras, P. / Saletti, P. / Roth, A. D. / Horber, D. / Buehlmann, M. et al. | 2016
- 862
-
Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancerJamal-Hanjani, M. / Wilson, G. A. / Horswell, S. / Mitter, R. / Sakarya, O. / Constantin, T. / Salari, R. / Kirkizlar, E. / Sigurjonsson, S. / Pelham, R. et al. | 2016
- 868
-
Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA studyNilsson, S. / Cislo, P. / Sartor, O. / Vogelzang, N. J. / Coleman, R. E. / O'Sullivan, J. M. / Reuning-Scherer, J. / Shan, M. / Zhan, L. / Parker, C. et al. | 2016
- 875
-
Prognostic factors in patients with poor-risk germ-cell tumors: a retrospective analysis of the Indiana University experience from 1990 to 2014†Adra, N. / Althouse, S. K. / Liu, H. / Brames, M. J. / Hanna, N. H. / Einhorn, L. H. / Albany, C. et al. | 2016
- 880
-
A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK)Powles, T. / Brown, J. / Larkin, J. / Jones, R. / Ralph, C. / Hawkins, R. / Chowdhury, S. / Boleti, E. / Bhal, A. / Fife, K. et al. | 2016
- 887
-
Spectrum of clinical and genetic features of patients with inherited platelet disorder with suspected predisposition to hematological malignancies: a nationwide survey in JapanYoshimi, A. / Toya, T. / Nannya, Y. / Takaoka, K. / Kirito, K. / Ito, E. / Nakajima, H. / Hayashi, Y. / Takahashi, T. / Moriya-Saito, A. et al. | 2016
- 895
-
Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab eraCheah, C. Y. / Chihara, D. / Ahmed, M. / Davis, R. E. / Nastoupil, L. J. / Phansalkar, K. / Hagemeister, F. B. / Fayad, L. E. / Westin, J. R. / Oki, Y. et al. | 2016
- 902
-
Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myelomaFouquet, G. / Pegourie, B. / Macro, M. / Petillon, M. O. / Karlin, L. / Caillot, D. / Roussel, M. / Arnulf, B. / Mathiot, C. / Marit, G. et al. | 2016
- 908
-
Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancerVillaflor, V. M. / Melotek, J. M. / Karrison, T. G. / Brisson, R. J. / Blair, E. A. / Portugal, L. / De Souza, J. A. / Ginat, D. T. / Stenson, K. M. / Langerman, A. et al. | 2016
- 914
-
Merkel cell carcinoma: value of sentinel lymph-node status and adjuvant radiation therapyServy, A. / Maubec, E. / Sugier, P. E. / Grange, F. / Mansard, S. / Lesimple, T. / Marinho, E. / Couturaud, B. / Girod, A. / Albert, S. et al. | 2016
- 920
-
What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)Drilon, A. / Li, G. / Dogan, S. / Gounder, M. / Shen, R. / Arcila, M. / Wang, L. / Hyman, D. M. / Hechtman, J. / Wei, G. et al. | 2016
- 926
-
The global decrease in cancer mortality: trends and disparitiesHashim, D. / Boffetta, P. / La Vecchia, C. / Rota, M. / Bertuccio, P. / Malvezzi, M. / Negri, E. et al. | 2016
- 933
-
Cancer mortality in cohorts of workers in the European rubber manufacturing industry first employed since 1975Boniol, M. / Koechlin, A. / Świątkowska, B. / Sorahan, T. / Wellmann, J. / Taeger, D. / Jakobsson, K. / Pira, E. / Boffetta, P. / La Vecchia, C. et al. | 2016
- 941
-
Periodontal disease and risk of all cancers among male never smokers: an updated analysis of the Health Professionals Follow-up StudyMichaud, D. S. / Kelsey, K. T. / Papathanasiou, E. / Genco, C. A. / Giovannucci, E. et al. | 2016
- 947
-
A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcomaThomas, S. / Aggarwal, R. / Jahan, T. / Ryan, C. / Troung, T. / Cripps, A. M. / Raha, P. / Thurn, K. T. / Chen, S. / Grabowsky, J. A. et al. | 2016
- 953
-
Ovarian suppression during chemotherapy increases pregnancy rate in survivorsBlumenfeld, Z. et al. | 2016
- 953
-
Transformation of ALK rearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinibTakegawa, N. / Hayashi, H. / Iizuka, N. / Takahama, T. / Ueda, H. / Tanaka, K. / Takeda, M. / Nakagawa, K. et al. | 2016
- 955
-
Extranodal extension is an important prognostic parameter for both colonic and rectal cancerLuchini, C. / Nottegar, A. / Pea, A. / Solmi, M. / Stubbs, B. / Capelli, P. / Sergi, G. / Manzato, E. / Fassan, M. / Wood, L. D. et al. | 2016
- 955
-
Prognostic impact of extracapsular lymph node involvement in colorectal cancerHuang, Q. / Qin, X. et al. | 2016
- 956
-
Prognostic impact of extra-nodal extension on colon and rectal cancer should be investigated separatelyHuang, Q. / Yang, H. et al. | 2016
- 957
-
Reply to the letter to the editor ‘A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma’ by Rosati et al.Hines, R. B. / Al-Rajabi, R. et al. | 2016
- 958
-
Reply to the letter to the editor ‘Number-Needed-To-Treat for pricing costly anti-cancer drugs. The example of Regorafenib in metastatic colorectal cancer’ by Graziano et al.Pignatti, F. / Martinalbo, J. / Jonsson, B. / Foggi, P. et al. | 2016
- 958
-
Dendritic cells stimulated by MUC1 antigen could induce lymphocytes' anergy through PD-L2 but not through PD-L1 patwayWojas-Krawczyk, K. / Homa-Mlak, I. / Krawczyk, P. / Kucharczyk, T. / Milanowski, J. et al. | 2016
- 961
-
Lessons from clinical trials on quality-of-life assessment in ovarian cancer trialsDi Maio, M. / Perrone, F. et al. | 2016
- 962
-
Diagnostic Gleason score and castration-resistant prostate cancerJayaram, A. / Attard, G. et al. | 2016
- 965
-
Risk factors, prevalence, and course of severe fatigue after breast cancer treatment: a meta-analysis involving 12 327 breast cancer survivorsAbrahams, H. J. / Gielissen, M. F. / Schmits, I. C. / Verhagen, C. A. / Rovers, M. M. / Knoop, H. et al. | 2016
- 975
-
Anti-tumour activity of platinum compounds in advanced prostate cancer—a systematic literature reviewHager, S. / Ackermann, C. J. / Joerger, M. / Gillessen, S. / Omlin, A. et al. | 2016
- 984
-
Cancer-associated toll-like receptor modulation and insinuation in infection susceptibility: association or coincidence?Khan, A. A. / Khan, Z. / Warnakulasuriya, S. et al. | 2016
- 998
-
Ocular toxicities of MEK inhibitors and other targeted therapiesStjepanovic, N. / Velazquez-Martin, J. P. / Bedard, P. L. et al. | 2016
- 1006
-
Health-related quality of life in women with recurrent ovarian cancer receiving paclitaxel plus trebananib or placebo (TRINOVA-1)†Fujiwara, K. / Monk, B. J. / Lhommé, C. / Coleman, R. L. / Brize, A. / Oaknin, A. / Ray-Coquard, I. / Fabbro, M. / Provencher, D. / Bamias, A. et al. | 2016
- 1013
-
Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safetyMatulonis, U. A. / Penson, R. T. / Domchek, S. M. / Kaufman, B. / Shapira-Frommer, R. / Audeh, M. W. / Kaye, S. / Molife, L. R. / Gelmon, K. A. / Robertson, J. D. et al. | 2016
- 1020
-
A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after first-line taxane and bevacizumab: a GINECO group studyTrédan, O. / Follana, P. / Moullet, I. / Cropet, C. / Trager-Maury, S. / Dauba, J. / Lavau-Denes, S. / Diéras, V. / Béal-Ardisson, D. / Gouttebel, M. et al. | 2016
- 1029
-
Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer†Michiels, S. / Pugliano, L. / Marguet, S. / Grun, D. / Barinoff, J. / Cameron, D. / Cobleigh, M. / Di Leo, A. / Johnston, S. / Gasparini, G. et al. | 2016
- 1035
-
Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2− early breast cancer: WSG-AGO EC-Doc TrialGluz, O. / Liedtke, C. / Huober, J. / Peyro-Saint-Paul, H. / Kates, R. E. / Kreipe, H. H. / Hartmann, A. / Pelz, E. / Erber, R. / Mohrmann, S. et al. | 2016
- 1041
-
Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trialMackey, J. R. / Pieńkowski, T. / Crown, J. / Sadeghi, S. / Martin, M. / Chan, A. / Saleh, M. / Sehdev, S. / Provencher, L. / Semiglazov, V. et al. | 2016
- 1047
-
Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trialHarbeck, N. / Iyer, S. / Turner, N. / Cristofanilli, M. / Ro, J. / André, F. / Loi, S. / Verma, S. / Iwata, H. / Bhattacharyya, H. et al. | 2016
- 1055
-
Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOXCiardiello, F. / Normanno, N. / Martinelli, E. / Troiani, T. / Pisconti, S. / Cardone, C. / Nappi, A. / Bordonaro, A. R. / Rachiglio, M. / Lambiase, M. et al. | 2016
- 1062
-
Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancerAmatu, A. / Barault, L. / Moutinho, C. / Cassingena, A. / Bencardino, K. / Ghezzi, S. / Palmeri, L. / Bonazzina, E. / Tosi, F. / Ricotta, R. et al. | 2016
- 1068
-
Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials†Overman, M. J. / Morris, V. / Kee, B. / Fogelman, D. / Xiao, L. / Eng, C. / Dasari, A. / Shroff, R. / Mazard, T. / Shaw, K. et al. | 2016
- 1074
-
Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safetyLuo, H. Y. / Li, Y. H. / Wang, W. / Wang, Z. Q. / Yuan, X. / Ma, D. / Wang, F. H. / Zhang, D. S. / Lin, D. R. / Lin, Y. C. et al. | 2016
- 1081
-
Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemiaYoon, J. H. / Yhim, H. Y. / Kwak, J. Y. / Ahn, J. S. / Yang, D. H. / Lee, J. J. / Kim, S. J. / Kim, J. S. / Park, S. J. / Choi, C. W. et al. | 2016
- 1088
-
Reduced intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after an autologous transplant achieves durable long-term disease control: an analysis from the Lymphoma Working Party of the EBMT†Robinson, S. P. / Boumendil, A. / Finel, H. / Schouten, H. / Ehninger, G. / Maertens, J. / Crawley, C. / Rambaldi, A. / Russell, N. / Anders, W. et al. | 2016
- 1095
-
The value of routine bone marrow biopsy in patients with diffuse large B-cell lymphoma staged with PET/CT: a Danish-Canadian study†Alzahrani, M. / El-Galaly, T. C. / Hutchings, M. / Hansen, J. W. / Loft, A. / Johnsen, H. E. / Iyer, V. / Wilson, D. / Sehn, L. H. / Savage, K. J. et al. | 2016
- 1100
-
Incidence and prognostic impact of other cancers in a population of long-term survivors of chronic lymphocytic leukemiaFalchi, L. / Vitale, C. / Keating, M. J. / Lerner, S. / Wang, X. / Elhor Gbito, K. Y. / Strom, S. / Wierda, W. G. / Ferrajoli, A. et al. | 2016
- 1107
-
Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV ‘real life’ trial on the variability of response to opioidsCorli, O. / Floriani, I. / Roberto, A. / Montanari, M. / Galli, F. / Greco, M. T. / Caraceni, A. / Kaasa, S. / Dragani, T. A. / Azzarello, G. et al. | 2016
- 1116
-
A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancersChi, K. N. / Yu, E. Y. / Jacobs, C. / Bazov, J. / Kollmannsberger, C. / Higano, C. S. / Mukherjee, S. D. / Gleave, M. E. / Stewart, P. S. / Hotte, S. J. et al. | 2016
- 1123
-
Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomasGaudio, E. / Tarantelli, C. / Kwee, I. / Barassi, C. / Bernasconi, E. / Rinaldi, A. / Ponzoni, M. / Cascione, L. / Targa, A. / Stathis, A. et al. | 2016
- 1129
-
Breast cancer incidence and mortality: trends over 40 years among women in Shanghai, ChinaHuang, Z. / Wen, W. / Zheng, Y. / Gao, Y. T. / Wu, C. / Bao, P. / Wang, C. / Gu, K. / Peng, P. / Gong, Y. et al. | 2016
- 1135
-
Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanomaSpain, L. / Higgins, R. / Gopalakrishnan, K. / Turajlic, S. / Gore, M. / Larkin, J. et al. | 2016
- 1138
-
Targeted treatment and immunotherapy in leptomeningeal metastases from melanomaGeukes Foppen, M. H. / Brandsma, D. / Blank, C. U. / van Thienen, J. V. / Haanen, J. B. / Boogerd, W. et al. | 2016
- 1143
-
Large-scale prospective pharmacogenomics study of oxaliplatin-induced neuropathy in colon cancer patients enrolled in the JFMC41-1001-C2 (JOIN Trial)Kanai, M. / Kawaguchi, T. / Kotaka, M. / Shinozaki, K. / Touyama, T. / Manaka, D. / Ishigure, K. / Hasegawa, J. / Munemoto, Y. / Matsui, T. et al. | 2016
- 1148
-
A genomic case study of mixed fibrolamellar hepatocellular carcinomaGriffith, O. L. / Griffith, M. / Krysiak, K. / Magrini, V. / Ramu, A. / Skidmore, Z. L. / Kunisaki, J. / Austin, R. / McGrath, S. / Zhang, J. et al. | 2016
- 1155
-
Tumourigenic non-small-cell lung cancer mesenchymal circulating tumour cells: a clinical case studyMorrow, C. J. / Trapani, F. / Metcalf, R. L. / Bertolini, G. / Hodgkinson, C. L. / Khandelwal, G. / Kelly, P. / Galvin, M. / Carter, L. / Simpson, K. L. et al. | 2016
- 1161
-
Rociletinib: has the TIGER lost a few of its stripes?Dhingra, K. et al. | 2016
- 1165
-
Osimertinib (AZD9291)—a science-driven, collaborative approach to rapid drug design and developmentYver, A. et al. | 2016
- 1171
-
Reply to the letter to the editor ‘A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma’ by Hines et al.Rosati, G. / Mosconi, P. / Torri, V. / Apolone, G. / Johnson, F. E. / Fossati, R. et al. | 2016
- 1171
-
What is the clinical impact of the LUX-Lung 5 trial?Addeo, A. et al. | 2016
- 1172
-
Reply to the letter to the editor ‘What is the clinical impact of the LUX-Lung 5 trial?’ by AddeoSchuler, M. / Yang, J. C. / Planchard, D. et al. | 2016
- 1173
-
Reply to the letter to the editor ‘Survival in young adults diagnosed with follicular lymphoma’ by Calvo et al.Conconi, A. / Montoto, S. / Montserrat, E. / Zucca, E. et al. | 2016
- 1174
-
The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanomaLee, B. / Wong, A. / Kee, D. / Neeson, P. / Shackleton, M. / McArthur, G. / Sandhu, S. et al. | 2016
- 1177
-
On the tumor risk from dental diagnostic X-ray exposureJargin, S. V. et al. | 2016
- 1177
-
Reply to the letter to the editor ‘On the tumor risk from dental diagnostic X-ray exposure’ by JarginLin, M. C. / Lee, C. F. / Kao, C. H. et al. | 2016
- 1178
-
Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumabCousin, S. / Toulmonde, M. / Kind, M. / Cazeau, A. L. / Bechade, D. / Coindre, J. M. / Italiano, A. et al. | 2016
- 1180
-
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancerO'Neil, B. H. / Scott, A. J. / Ma, W. W. / Cohen, S. J. / Aisner, D. L. / Menter, A. R. / Tejani, M. A. / Cho, J. K. / Granfortuna, J. / Coveler, A. L. et al. | 2016
- 1181
-
Breast cancer genetic risk profile is differentially associated with interval and screen-detected breast cancersLi, J. / Holm, J. / Bergh, J. / Eriksson, M. / Darabi, H. / Lindström, L. S. / Törnberg, S. / Hall, P. / Czene, K. et al. | 2016
- 1183
-
A tribute to the life and career of Holbrook KohrtMarabelle, A. / Houot, R. et al. | 2016
- 1185
-
Statistical controversies in clinical research: the importance of importanceGleiss, A. / Zeillinger, R. / Braicu, E. I. / Trillsch, F. / Vergote, I. / Schemper, M. et al. | 2016
- 1190
-
Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapiesSanmamed, M. F. / Chester, C. / Melero, I. / Kohrt, H. et al. | 2016
- 1199
-
Biomarkers associated with checkpoint inhibitorsManson, G. / Norwood, J. / Marabelle, A. / Kohrt, H. / Houot, R. et al. | 2016
- 1207
-
CNS infections in patients with hematological disorders (including allogeneic stem-cell transplantation)—Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)Schmidt-Hieber, M. / Silling, G. / Schalk, E. / Heinz, W. / Panse, J. / Penack, O. / Christopeit, M. / Buchheidt, D. / Meyding-Lamadé, U. / Hähnel, S. et al. | 2016
- 1226
-
Clinical experience with lenalidomide alone or in combination with rituximab in indolent B-cell and mantle cell lymphomasRuan, J. / Shah, B. / Martin, P. / Schuster, S. J. et al. | 2016
- 1235
-
Impact of a tailored oral vitamin D supplementation regimen on serum 25-hydroxyvitamin D levels in early breast cancer patients: a randomized phase III study†Jacot, W. / Firmin, N. / Roca, L. / Topart, D. / Gallet, S. / Durigova, A. / Mirr, S. / Abach, L. / Pouderoux, S. / D'Hondt, V. et al. | 2016
- 1241
-
Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrenceMittendorf, E. A. / Ardavanis, A. / Symanowski, J. / Murray, J. L. / Shumway, N. M. / Litton, J. K. / Hale, D. F. / Perez, S. A. / Anastasopoulou, E. A. / Pistamaltzian, N. F. et al. | 2016
- 1249
-
Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study†Martin, M. / Fumoleau, P. / Dewar, J. A. / Albanell, J. / Limentani, S. A. / Campone, M. / Chang, J. C. / Patre, M. / Strasak, A. / de Haas, S. L. et al. | 2016
- 1257
-
Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcomaMatsuo, K. / Takazawa, Y. / Ross, M. S. / Elishaev, E. / Podzielinski, I. / Yunokawa, M. / Sheridan, T. B. / Bush, S. H. / Klobocista, M. M. / Blake, E. A. et al. | 2016
- 1266
-
A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC)Oki, E. / Murata, A. / Yoshida, K. / Maeda, K. / Ikejiri, K. / Munemoto, Y. / Sasaki, K. / Matsuda, C. / Kotake, M. / Suenaga, T. et al. | 2016
- 1273
-
Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM studyFolprecht, G. / Pericay, C. / Saunders, M. P. / Thomas, A. / Lopez Lopez, R. / Roh, J. K. / Chistyakov, V. / Höhler, T. / Kim, J. S. / Hofheinz, R. D. et al. | 2016
- 1280
-
Pemetrexed plus carboplatin versus pemetrexed in pretreated patients with advanced non-squamous non-small-cell lung cancer: treating the right patients based on individualized treatment effect prediction†van Kruijsdijk, R. C. / Visseren, F. L. / Boni, L. / Groen, H. J. / Dingemans, A. M. / Aerts, J. G. / van der Graaf, Y. / Ardizzoni, A. / Smit, E. F. et al. | 2016
- 1286
-
Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancersDrilon, A. / Bergagnini, I. / Delasos, L. / Sabari, J. / Woo, K. M. / Plodkowski, A. / Wang, L. / Hellmann, M. D. / Joubert, P. / Sima, C. S. et al. | 2016
- 1291
-
Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancerChatterjee, M. / Turner, D. C. / Felip, E. / Lena, H. / Cappuzzo, F. / Horn, L. / Garon, E. B. / Hui, R. / Arkenau, H. T. / Gubens, M. A. et al. | 2016
- 1299
-
Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA)Tandstad, T. / Ståhl, O. / Dahl, O. / Haugnes, H. S. / Håkansson, U. / Karlsdottir, . / Kjellman, A. / Langberg, C. W. / Laurell, A. / Oldenburg, J. et al. | 2016
- 1304
-
Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)–tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinomaNadal, R. / Amin, A. / Geynisman, D. M. / Voss, M. H. / Weinstock, M. / Doyle, J. / Zhang, Z. / Viudez, A. / Plimack, E. R. / McDermott, D. F. et al. | 2016
- 1311
-
Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatmentPouessel, D. / Neuzillet, Y. / Mertens, L. S. / van der Heijden, M. S. / de Jong, J. / Sanders, J. / Peters, D. / Leroy, K. / Manceau, A. / Maille, P. et al. | 2016
- 1317
-
Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomesCheah, C. Y. / Chihara, D. / Horowitz, S. / Sevin, A. / Oki, Y. / Zhou, S. / Fowler, N. H. / Romaguera, J. E. / Turturro, F. / Hagemeister, F. B. et al. | 2016
- 1323
-
Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHLKoch, K. / Hoster, E. / Ziepert, M. / Unterhalt, M. / Ott, G. / Rosenwald, A. / Hansmann, M. L. / Bernd, W. / Stein, H. / Pöschel, V. et al. | 2016
- 1329
-
Oral health and risk of colorectal cancer: results from three cohort studies and a meta-analysisRen, H. G. / Luu, H. N. / Cai, H. / Xiang, Y. B. / Steinwandel, M. / Gao, Y. T. / Hargreaves, M. / Zheng, W. / Blot, W. J. / Long, J. R. et al. | 2016
- 1336
-
Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classesChung, J. H. / Sanford, E. / Johnson, A. / Klempner, S. J. / Schrock, A. B. / Palma, N. A. / Erlich, R. L. / Frampton, G. M. / Chalmers, Z. R. / Vergilio, J. et al. | 2016
- 1342
-
Pragmatic randomized clinical trials: a proposal to enhance evaluation of new cancer therapies with early signs of exceptional activityKoehler, M. / Donnelly, E. T. / Kalanovic, D. / Dagher, R. / Rothenberg, M. L. et al. | 2016
- 1349
-
Inhibition of Hedgehog signaling for the treatment of lymphoma and CLL: a phase II study from the LYSAHouot, R. / Soussain, C. / Tilly, H. / Haioun, C. / Thieblemont, C. / Casasnovas, O. / Bouabdallah, K. / Morschhauser, F. / Le Gouill, S. / Salles, G. A. et al. | 2016
- 1351
-
Reply to the letter to the editor ‘Insertion of central venous catheters (CVCs): any changes in the past ten years’ by Biffi et al.Pinto, D. / Gouveia, P. / Sousa, B. / Hutka, M. / Furlanetto, J. / Mariz, J. M. / Wuerstlein, R. / Cardoso, F. et al. | 2016
- 1351
-
Insertion of central venous catheters (CVCs): any changes in the past 10 years?Biffi, R. / Bertoglio, S. / Pittiruti, M. et al. | 2016
- 1352
-
Pembrolizumab-induced necrotic myositis in a patient with metastatic melanomaVallet, H. / Gaillet, A. / Weiss, N. / Vanhaecke, C. / Saheb, S. / Touitou, V. / Franck, N. / Kramkimel, N. / Borden, A. / Touat, M. et al. | 2016
- 1353
-
Safety of the PD-1 antibody pembrolizumab in patients with high-grade adverse events under ipilimumab treatment†Bender, C. / Dimitrakopoulou-Strauss, A. / Enk, A. / Hassel, J. C. et al. | 2016
- 1354
-
Severe exacerbation or manifestation of primary disease related to nivolumab in non-small-cell lung cancer patients with poor performance status or brain metastasesKanai, O. / Fujita, K. / Okamura, M. / Nakatani, K. / Mio, T. et al. | 2016
- 1356
-
Activity of immune checkpoint inhibition in platinum refractory germ-cell tumorsZschäbitz, S. / Lasitschka, F. / Jäger, D. / Grüllich, C. et al. | 2016
- 1360
-
Abandoning diesel because of health perspectives: are there reasonable alternatives?Vreugdenhil, G. / Mannaerts, H. F. et al. | 2016
- 1361
-
Reply to the letter to the editor ‘Abandoning diesel because of health perspectives: are there reasonable alternatives?’ by Vreugdenhil and MannaertsSwanton, C. / Boffetta, P. / Peston, R. / Soria, J. C. et al. | 2016
- 1362
-
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodiesNaidoo, J. / Page, D. B. / Li, B. T. / Connell, L. C. / Schindler, K. / Lacouture, M. E. / Postow, M. A. / Wolchok, J. D. et al. | 2016
- 1365
-
Is CA125 useful in monitoring patients with platinum-resistant ovarian cancer?Rustin, G. J. / Hall, M. R. et al. | 2016
- 1366
-
Prognostic pathways in early-stage ovarian cancer: can gene expression transcend histological subtype?McNeish, I. A. et al. | 2016
- 1368
-
PIK3CA mutations in HER2-positive breast cancer: an ongoing conundrumGoel, S. / Krop, I. E. et al. | 2016
- 1372
-
A tribute to biologics in advanced colorectal cancer treatmentSobrero, A. et al. | 2016
- 1374
-
Necitumumab in squamous non-small-cell lung cancer: how to move forward?Garrido, P. / Palacios, J. et al. | 2016
- 1376
-
Where next in kidney cancer?Powles, T. et al. | 2016
- 1378
-
ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology—edition 2016Dittrich, C. / Kosty, M. / Jezdic, S. / Pyle, D. / Berardi, R. / Bergh, J. / El Saghir, N. / Lotz, J. P. / Österlund, P. / Pavlidis, N. et al. | 2016
- 1382
-
International cancer seminars: a focus on kidney cancerScelo, G. / Hofmann, J. N. / Banks, R. E. / Bigot, P. / Bhatt, R. S. / Cancel-Tassin, G. / Chew, S. K. / Creighton, C. J. / Cussenot, O. / Davis, I. J. et al. | 2016
- 1386
-
ESMO consensus guidelines for the management of patients with metastatic colorectal cancerVan Cutsem, E. / Cervantes, A. / Adam, R. / Sobrero, A. / Van Krieken, J. H. / Aderka, D. / Aranda Aguilar, E. / Bardelli, A. / Benson, A. / Bodoky, G. et al. | 2016
- 1423
-
ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in EuropeCherny, N. / Sullivan, R. / Torode, J. / Saar, M. / Eniu, A. et al. | 2016
- 1443
-
Consensus on precision medicine for metastatic cancers: a report from the MAP conferenceSwanton, C. / Soria, J. C. / Bardelli, A. / Biankin, A. / Caldas, C. / Chandarlapaty, S. / de Koning, L. / Dive, C. / Feunteun, J. / Leung, S. Y. et al. | 2016
- 1449
-
BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancerMoschetta, M. / George, A. / Kaye, S. B. / Banerjee, S. et al. | 2016
- 1456
-
Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratorySartore-Bianchi, A. / Loupakis, F. / Argilés, G. / Prager, G. W. et al. | 2016
- 1467
-
The impact of the revolution in hepatitis C treatment on hepatocellular carcinomaWirth, T. C. / Manns, M. P. et al. | 2016
- 1474
-
Current management of newly diagnosed acute promyelocytic leukemiaCicconi, L. / Lo-Coco, F. et al. | 2016
- 1482
-
Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapyPitt, J. M. / Marabelle, A. / Eggermont, A. / Soria, J. C. / Kroemer, G. / Zitvogel, L. et al. | 2016
- 1492
-
Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)Kim, J. M. / Chen, D. S. et al. | 2016
- 1505
-
Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trialLindemann, K. / Kristensen, G. / Mirza, M. R. / Davies, L. / Hilpert, F. / Romero, I. / Ayhan, A. / Burges, A. / Rubio, M. J. / Raspagliesi, F. et al. | 2016
- 1511
-
A prognostic regulatory pathway in stage I epithelial ovarian cancer: new hints for the poor prognosis assessmentCalura, E. / Paracchini, L. / Fruscio, R. / DiFeo, A. / Ravaggi, A. / Peronne, J. / Martini, P. / Sales, G. / Beltrame, L. / Bignotti, E. et al. | 2016
- 1519
-
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab†Loibl, S. / Majewski, I. / Guarneri, V. / Nekljudova, V. / Holmes, E. / Bria, E. / Denkert, C. / Schem, C. / Sotiriou, C. / Loi, S. et al. | 2016
- 1525
-
Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapyPivot, X. / Marmé, F. / Koenigsberg, R. / Guo, M. / Berrak, E. / Wolfer, A. et al. | 2016
- 1532
-
Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somaticWinter, C. / Nilsson, M. P. / Olsson, E. / George, A. M. / Chen, Y. / Kvist, A. / Törngren, T. / Vallon-Christersson, J. / Hegardt, C. / Häkkinen, J. et al. | 2016
- 1539
-
Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)Yamazaki, K. / Nagase, M. / Tamagawa, H. / Ueda, S. / Tamura, T. / Murata, K. / Eguchi Nakajima, T. / Baba, E. / Tsuda, M. / Moriwaki, T. et al. | 2016
- 1546
-
P21-activated kinase 1 (Pak1) signaling influences therapeutic outcome in pancreatic cancerJagadeeshan, S. / Subramanian, A. / Tentu, S. / Beesetti, S. / Singhal, M. / Raghavan, S. / Surabhi, R. P. / Mavuluri, J. / Bhoopalan, H. / Biswal, J. et al. | 2016
- 1557
-
PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancerSclafani, F. / Brown, G. / Cunningham, D. / Wotherspoon, A. / Tait, D. / Peckitt, C. / Evans, J. / Yu, S. / Sena Teixeira Mendes, L. / Tabernero, J. et al. | 2016
- 1565
-
CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)†Michl, M. / Stintzing, S. / Fischer von Weikersthal, L. / Decker, T. / Kiani, A. / Vehling-Kaiser, U. / Al-Batran, S. E. / Heintges, T. / Lerchenmueller, C. / Kahl, C. et al. | 2016
- 1573
-
Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin plus necitumumab versus gemcitabine–cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancerPaz-Ares, L. / Socinski, M. A. / Shahidi, J. / Hozak, R. R. / Soldatenkova, V. / Kurek, R. / Varella-Garcia, M. / Thatcher, N. / Hirsch, F. R. et al. | 2016
- 1579
-
Efficacy of the nanoparticle–drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I–IIa clinical trialKeefe, S. M. / Hoffman-Censits, J. / Cohen, R. B. / Mamtani, R. / Heitjan, D. / Eliasof, S. / Nixon, A. / Turnbull, B. / Garmey, E. G. / Gunnarsson, O. et al. | 2016
- 1585
-
Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial†Clement, P. M. / Gauler, T. / Machiels, J. P. / Haddad, R. I. / Fayette, J. / Licitra, L. F. / Tahara, M. / Cohen, E. E. / Cupissol, D. / Grau, J. J. et al. | 2016
- 1594
-
Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer†Argiris, A. / Bauman, J. E. / Ohr, J. / Gooding, W. E. / Heron, D. E. / Duvvuri, U. / Kubicek, G. J. / Posluszny, D. M. / Vassilakopoulou, M. / Kim, S. et al. | 2016
- 1601
-
Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE studySuzuki, K. / Yamanaka, T. / Hashimoto, H. / Shimada, Y. / Arata, K. / Matsui, R. / Goto, K. / Takiguchi, T. / Ohyanagi, F. / Kogure, Y. et al. | 2016
- 1607
-
Factors associated with depression and anxiety symptoms in family caregivers of patients with incurable cancer†Nipp, R. D. / El-Jawahri, A. / Fishbein, J. N. / Gallagher, E. R. / Stagl, J. M. / Park, E. R. / Jackson, V. A. / Pirl, W. F. / Greer, J. A. / Temel, J. S. et al. | 2016
- 1612
-
Relationship between efficacy outcomes and weight gain during treatment of advanced, non-squamous, non-small-cell lung cancer patientsPatel, J. D. / Pereira, J. R. / Chen, J. / Liu, J. / Guba, S. C. / John, W. J. / Orlando, M. / Scagliotti, G. / Bonomi, P. D. et al. | 2016
- 1619
-
The role of oral hygiene in head and neck cancer: results from International Head and Neck Cancer Epidemiology (INHANCE) consortiumHashim, D. / Sartori, S. / Brennan, P. / Curado, M. P. / Wünsch-Filho, V. / Divaris, K. / Olshan, A. F. / Zevallos, J. P. / Winn, D. M. / Franceschi, S. et al. | 2016
- 1625
-
Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial†Eigentler, T. K. / Gutzmer, R. / Hauschild, A. / Heinzerling, L. / Schadendorf, D. / Nashan, D. / Hölzle, E. / Kiecker, F. / Becker, J. / Sunderkötter, C. et al. | 2016
- 1633
-
How to report toxicity associated with targeted therapies?Cabarrou, B. / Boher, J. M. / Bogart, E. / Tresch-Bruneel, E. / Penel, N. / Ravaud, A. / Escudier, B. / Mahier Ait-Oukhatar, C. / Delord, J. P. / Roché, H. et al. | 2016
- 1638
-
The time to progression ratio: a new individualized volumetric parameter for the early detection of clinical benefit of targeted therapiesCirkel, G. A. / Weeber, F. / Bins, S. / Gadellaa-van Hooijdonk, C. G. / van Werkhoven, E. / Willems, S. M. / van Stralen, M. / Veldhuis, W. B. / Ubink, I. / Steeghs, N. et al. | 2016
- 1644
-
Precision medicine and oncology: an overview of the opportunities presented by next-generation sequencing and big data and the challenges posed to conventional drug development and regulatory approval pathwaysDoherty, M. / Metcalfe, T. / Guardino, E. / Peters, E. / Ramage, L. et al. | 2016
- 1647
-
Significance of the prognostic stratification of extranodal extension in colorectal cancerLuchini, C. / Nottegar, A. / Pea, A. / Solmi, M. / Stubbs, B. / Capelli, P. / Sergi, G. / Manzato, E. / Fassan, M. / Wood, L. D. et al. | 2016
- 1647
-
Positron emission tomography (PET) as a predictive measure in patients with metastatic pancreatic cancer and normal CA19-9 levels at baselineRamanathan, R. K. / Korn, R. L. / Chiorean, E. G. / Liu, H. / Von Hoff, D. D. et al. | 2016
- 1648
-
The challenge to one-course carboplatin in seminoma clinical stage 1Dieckmann, K. P. / Anheuser, P. et al. | 2016
- 1649
-
Anti-PD-1-associated organizing pneumonia in a responding melanoma patientFiset, P. O. / Shapera, S. / Butler, M. O. / Tsao, M. S. et al. | 2016
- 1650
-
Pulmonary sarcoidosis induced by the anti-PD-1 monoclonal antibody pembrolizumab or post-immunotherapy granulomatous reaction: which is more appropriate terminology?Paydas, S. et al. | 2016
- 1651
-
Benefit of therapeutic drug monitoring to disclose pharmacokinetic interaction between sunitinib and calcium channel blockerDa Silva, F. / Thomas-Schoemann, A. / Huillard, O. / Goldwasser, F. / Blanchet, B. et al. | 2016
- 1652
-
Reply to ‘Statistical controversies in clinical research: end points other than survival are vital for regulatory approval of anticancer agents’ by Saad and Buysevan Halteren, H. K. et al. | 2016
- 1653
-
Response to the letter to the editor ‘Reply to “Statistical controversies in clinical research: end points other than survival are vital for regulatory approval of anticancer agents” by H. K. van Halteren’Saad, E. D. / Buyse, M. et al. | 2016
- 1655
-
New goalsSoria, J. C. et al. | 2016
- 1656
-
Saving the best treatment for last?Coleman, R. L. / Monk, B. J. et al. | 2016
- 1658
-
PD-L1 expression in penile cancer: a new frontier for immune checkpoint inhibitors?Al-Ahmadie, H. et al. | 2016
- 1660
-
Communication in oncology: now we train - but how well?†Stiefel, F. / Bourquin, C. et al. | 2016
- 1664
-
Cervical esophageal cancer: a gap in cancer knowledgeHoeben, A. / Polak, J. / Van De Voorde, L. / Hoebers, F. / Grabsch, H. I. / de Vos-Geelen, J. et al. | 2016
- 1675
-
The promise of immunotherapy in head and neck squamous cell carcinomaEconomopoulou, P. / Agelaki, S. / Perisanidis, C. / Giotakis, E. I. / Psyrri, A. et al. | 2016
- 1685
-
Sequential pathogenesis of metastatic VHL mutant clear cell renal cell carcinoma: putting it together with a translational perspectiveShenoy, N. / Pagliaro, L. et al. | 2016
- 1696
-
The forgotten woman's cancer: vulvar squamous cell carcinoma (VSCC) and a targeted approach to therapyClancy, A. A. / Spaans, J. N. / Weberpals, J. I. et al. | 2016
- 1706
-
Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approachesUdager, A. M. / Liu, T. Y. / Skala, S. L. / Magers, M. J. / McDaniel, A. S. / Spratt, D. E. / Feng, F. Y. / Siddiqui, J. / Cao, X. / Fields, K. L. et al. | 2016
- 1712
-
A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancerLacouture, M. E. / Keefe, D. M. / Sonis, S. / Jatoi, A. / Gernhardt, D. / Wang, T. / Doherty, J. P. / Giri, N. / Nadanaciva, S. / O'Connell, J. et al. | 2016
- 1719
-
Safety of everolimus plus exemestane in patients with hormone-receptor–positive, HER2–negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)Jerusalem, G. / Mariani, G. / Ciruelos, E. M. / Martin, M. / Tjan-Heijnen, V. C. / Neven, P. / Gavila, J. G. / Michelotti, A. / Montemurro, F. / Generali, D. et al. | 2016
- 1725
-
Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational studyDelaloge, S. / Pérol, D. / Courtinard, C. / Brain, E. / Asselain, B. / Bachelot, T. / Debled, M. / Dieras, V. / Campone, M. / Levy, C. et al. | 2016
- 1733
-
Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trialTrillsch, F. / Mahner, S. / Hilpert, F. / Davies, L. / García-Martínez, E. / Kristensen, G. / Savarese, A. / Vuylsteke, P. / Los, M. / Zagouri, F. et al. | 2016
- 1740
-
Long-term significance of urinary neopterin in ovarian cancer: a study by the Austrian Association for Gynecologic Oncology (AGO)Volgger, B. M. / Windbichler, G. H. / Zeimet, A. G. / Graf, A. H. / Bogner, G. / Angleitner-Boubenizek, L. / Rohde, M. / Denison, U. / Sliutz, G. / Fuith, L. C. et al. | 2016
- 1746
-
Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study groupModest, D. P. / Ricard, I. / Heinemann, V. / Hegewisch-Becker, S. / Schmiegel, W. / Porschen, R. / Stintzing, S. / Graeven, U. / Arnold, D. / von Weikersthal, L. F. et al. | 2016
- 1754
-
Stepped care targeting psychological distress in head and neck cancer and lung cancer patients: a randomized, controlled trialKrebber, A. M. / Jansen, F. / Witte, B. I. / Cuijpers, P. / de Bree, R. / Becker-Commissaris, A. / Smit, E. F. / van Straten, A. / Eeckhout, A. M. / Beekman, A. T. et al. | 2016
- 1761
-
Fatigue in people with localized colorectal cancer who do and do not receive chemotherapy: a longitudinal prospective studyVardy, J. L. / Dhillon, H. M. / Pond, G. R. / Renton, C. / Dodd, A. / Zhang, H. / Clarke, S. J. / Tannock, I. F. et al. | 2016
- 1768
-
Relative effectiveness assessments of oncology medicines for pricing and reimbursement decisions in European countriesKleijnen, S. / Lipska, I. / Leonardo Alves, T. / Meijboom, K. / Elsada, A. / Vervölgyi, V. / d'Andon, A. / Timoney, A. / Leufkens, H. G. / De Boer, A. et al. | 2016
- 1776
-
To be in pain (or not): a computer enables outpatients to inform their physicianOldenmenger, W. H. / Witkamp, F. E. / Bromberg, J. E. / Jongen, J. L. / Lieverse, P. J. / Huygen, F. J. / Baan, M. A. / van Zuylen, L. / van der Rijt, C. C. et al. | 2016
- 1782
-
Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma†Simonelli, M. / Zucali, P. / Santoro, A. / Thomas, M. B. / de Braud, F. G. / Borghaei, H. / Berlin, J. / Denlinger, C. S. / Noberasco, C. / Rimassa, L. et al. | 2016
- 1788
-
Identification of genetic variants in pharmacokinetic genes associated with Ewing Sarcoma treatment outcomeRuiz-Pinto, S. / Pita, G. / Patiño-García, A. / García-Miguel, P. / Alonso, J. / Pérez-Martínez, A. / Sastre, A. / Gómez-Mariano, G. / Lissat, A. / Scotlandi, K. et al. | 2016
- 1794
-
Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapyBen-Ami, E. / Barysauskas, C. M. / von Mehren, M. / Heinrich, M. C. / Corless, C. L. / Butrynski, J. E. / Morgan, J. A. / Wagner, A. J. / Choy, E. / Yap, J. T. et al. | 2016
- 1799
-
Inclusion of elderly patients in oncology clinical trialsLe Saux, O. / Falandry, C. / Gan, H. K. / You, B. / Freyer, G. / Péron, J. et al. | 2016
- 1805
-
Oncolytic immunotherapy: an emerging new modality for the treatment of cancerCoffin, R. S. et al. | 2016
- 1809
-
Reply to ‘The challenge to one course carboplatin in seminoma clinical stage 1’ by Dieckmann and AnheuserTandstad, T. / Cohn-Cedermark, G. et al. | 2016
- 1810
-
Safety profile of capecitabine as maintenance treatment after induction with XELOX or FOLFOX in metastatic colorectal cancer patientsCremolini, C. / Moretto, R. / Masi, G. / Falcone, A. et al. | 2016
- 1810
-
Reply to ‘Safety profile of capecitabine as maintenance treatment after XELOX or FOLFOX in metastatic colorectal cancer patients’ by C. Cremolini et al.Luo, H. Y. / Xu, R. H. et al. | 2016
- 1811
-
Histone deacetylase (HDAC) inhibitors when combined with a proteasome inhibitor are safe and effective in patients with extranodal natural killer/T-cell lymphoma (ENKTL)Tan, D. / Diong, C. P. / Loh, Y. / Goh, Y. T. et al. | 2016
- 1812
-
Challenging the soaring price of cancer medicines: a call for equity and transparencyGonçalves, A. / Maraninchi, D. / Vernant, J. P. et al. | 2016
- 1813
-
Successful treatment of refractory leiomyosarcoma with the PD-1 inhibitor nivolumabHeine, A. / Kristiansen, G. / Schild, H. H. / Brossart, P. et al. | 2016
- 1815
-
Searching for aurora in the night of sarcoma phase II trials: isn't it time to move to second gear?Toulmonde, M. et al. | 2016
- 1818
-
Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis†De Ruysscher, D. / Lueza, B. / Le Péchoux, C. / Johnson, D. H. / O'Brien, M. / Murray, N. / Spiro, S. / Wang, X. / Takada, M. / Lebeau, B. et al. | 2016
- 1829
-
Chemotherapy remains an essential element of personalized care for persons with lung cancersHellmann, M. D. / Li, B. T. / Chaft, J. E. / Kris, M. G. et al. | 2016
- 1836
-
Prognostic role of tumor PIK3CA mutation in colorectal cancer: a systematic review and meta-analysisMei, Z. B. / Duan, C. Y. / Li, C. B. / Cui, L. / Ogino, S. et al. | 2016
- 1848
-
Best practice guidelines in the psychosocial management of HPV-related head and neck cancer: recommendations from the European Head and Neck Cancer Society's Make Sense CampaignReich, M. / Licitra, L. / Vermorken, J. B. / Bernier, J. / Parmar, S. / Golusinski, W. / Castellsagué, X. / Leemans, C. R. et al. | 2016
- 1855
-
Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma†Dickson, M. A. / Mahoney, M. R. / Tap, W. D. / D'Angelo, S. P. / Keohan, M. L. / Van Tine, B. A. / Agulnik, M. / Horvath, L. E. / Nair, J. S. / Schwartz, G. K. et al. | 2016
- 1860
-
Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancersFumagalli, D. / Wilson, T. R. / Salgado, R. / Lu, X. / Yu, J. / O'Brien, C. / Walter, K. / Huw, L. Y. / Criscitiello, C. / Laios, I. et al. | 2016
- 1867
-
Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trialDieci, M. V. / Prat, A. / Tagliafico, E. / Paré, L. / Ficarra, G. / Bisagni, G. / Piacentini, F. / Generali, D. G. / Conte, P. / Guarneri, V. et al. | 2016
- 1873
-
Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)Mavroudis, D. / Matikas, A. / Malamos, N. / Papakotoulas, P. / Kakolyris, S. / Boukovinas, I. / Athanasiadis, A. / Kentepozidis, N. / Ziras, N. / Katsaounis, P. et al. | 2016
- 1879
-
Circulating microRNA-1290 as a novel diagnostic and prognostic biomarker in human colorectal cancerImaoka, H. / Toiyama, Y. / Fujikawa, H. / Hiro, J. / Saigusa, S. / Tanaka, K. / Inoue, Y. / Mohri, Y. / Mori, T. / Kato, T. et al. | 2016
- 1887
-
Improved survival with dose-escalated radiotherapy in stage III non-small-cell lung cancer: analysis of the National Cancer DatabaseBrower, J. V. / Amini, A. / Chen, S. / Hullett, C. R. / Kimple, R. J. / Wojcieszynski, A. P. / Bassetti, M. / Witek, M. E. / Yu, M. / Harari, P. M. et al. | 2016
- 1895
-
Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)†Joerger, M. / von Pawel, J. / Kraff, S. / Fischer, J. R. / Eberhardt, W. / Gauler, T. C. / Mueller, L. / Reinmuth, N. / Reck, M. / Kimmich, M. et al. | 2016
- 1902
-
A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinomaHo, A. L. / Dunn, L. / Sherman, E. J. / Fury, M. G. / Baxi, S. S. / Chandramohan, R. / Dogan, S. / Morris, L. G. / Cullen, G. D. / Haque, S. et al. | 2016
- 1909
-
Is it best to expect the worst? Influence of patients' side-effect expectations on endocrine treatment outcome in a 2-year prospective clinical cohort studyNestoriuc, Y. / von Blanckenburg, P. / Schuricht, F. / Barsky, A. J. / Hadji, P. / Albert, U. S. / Rief, W. et al. | 2016
- 1916
-
A randomized trial on chlorhexidine dressings for the prevention of catheter-related bloodstream infections in neutropenic patientsBiehl, L. M. / Huth, A. / Panse, J. / Krämer, C. / Hentrich, M. / Engelhardt, M. / Schäfer-Eckart, K. / Kofla, G. / Kiehl, M. / Wendtner, C. M. et al. | 2016
- 1922
-
Selection of an early biomarker for vascular normalization using dynamic contrast-enhanced ultrasonography to predict outcomes of metastatic patients treated with bevacizumabLassau, N. / Coiffier, B. / Kind, M. / Vilgrain, V. / Lacroix, J. / Cuinet, M. / Taieb, S. / Aziza, R. / Sarran, A. / Labbe-Devilliers, C. et al. | 2016
- 1928
-
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomasPatnaik, A. / Appleman, L. J. / Tolcher, A. W. / Papadopoulos, K. P. / Beeram, M. / Rasco, D. W. / Weiss, G. J. / Sachdev, J. C. / Chadha, M. / Fulk, M. et al. | 2016
- 1940
-
Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 studyLong, G. V. / Atkinson, V. / Ascierto, P. A. / Robert, C. / Hassel, J. C. / Rutkowski, P. / Savage, K. J. / Taylor, F. / Coon, C. / Gilloteau, I. et al. | 2016
- 1947
-
Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT)Saiag, P. / Gutzmer, R. / Ascierto, P. A. / Maio, M. / Grob, J. J. / Murawa, P. / Dreno, B. / Ross, M. / Weber, J. / Hauschild, A. et al. | 2016
- 1953
-
Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancerMansfield, A. S. / Aubry, M. C. / Moser, J. C. / Harrington, S. M. / Dronca, R. S. / Park, S. S. / Dong, H. et al. | 2016
- 1959
-
Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNAGremel, G. / Lee, R. J. / Girotti, M. R. / Mandal, A. K. / Valpione, S. / Garner, G. / Ayub, M. / Wood, S. / Rothwell, D. G. / Fusi, A. et al. | 2016
- 1966
-
Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapyNovotny, J. F. / Cogswell, J. / Inzunza, H. / Harbison, C. / Horak, C. / Averbuch, S. et al. | 2016
- 1970
-
Chemoprevention of hepatocellular carcinoma in people affected by hepatitis C virus: what changes does the introduction of direct-acting antiviral agents make?Testino, G. / Leone, S. et al. | 2016
- 1971
-
Preoperative chemoradiotherapy with cisplatin and docetaxel for stage IIIB non-small-cell lung cancer: 10-year follow-up of the SAKK 16/01 trialFrüh, M. / Ris, H. B. / Xyrafas, A. / Peters, S. / Mirimanoff, R. O. / Gautschi, O. / Pless, M. / Stupp, R. et al. | 2016
- 1971
-
Reply to ‘Chemoprevention of hepatocellular carcinoma in people affected by hepatitis C virus: what changes does the introduction of direct-acting antiviral agents make?’Wirth, T. C. / Manns, M. P. et al. | 2016
- 1973
-
Is radical chemo-radiotherapy appropriate in patients with stage IV non-small-cell lung cancer due to cervical lymph node metastases?de Boer, P. / Dahele, M. R. / Senan, S. et al. | 2016
- 1974
-
The clinical dilemma of grade 3 follicular lymphomaSorigue, M. / Ribera, J. M. / Sancho, J. M. et al. | 2016
- 1974
-
Pulmonary sarcoidosis or post-immunotherapy granulomatous reaction induced by the anti-PD-1 monoclonal antibody pembrolizumab: the terminology is not the key pointCousin, S. / Italiano, A. et al. | 2016
- 1975
-
Ipilimumab-related hypophysitis may precede severe CNS immune attackKöessler, T. / Olivier, T. / Fertani, S. / Marinari, E. / Dutoit, V. / Dietrich, P. Y. et al. | 2016
- 1977
-
Ovarian cancer mortality trends: which factors are involved?Weiderpass, E. / Botteri, E. et al. | 2016
- 1978
-
The role of opioids in cancer progression: emerging experimental and clinical implicationsSjøgren, P. / Kaasa, S. et al. | 2016
- 1981
-
Statistical controversies in clinical research: should schedules of tumor size assessments be changed?Filleron, T. / Kouokam, W. / Gilhodes, J. / Duhamel, A. / Penel, N. / Joly, F. / Tresch-Bruneel, E. / Kramar, A. / Houédé, N. et al. | 2016
- 1988
-
The obese endometrial cancer patient: how do we effectively improve morbidity and mortality in this patient population?Papatla, K. / Huang, M. / Slomovitz, B. et al. | 2016
- 1994
-
Fertility-sparing surgery in epithelial ovarian cancer: a systematic review of oncological issuesBentivegna, E. / Gouy, S. / Maulard, A. / Pautier, P. / Leary, A. / Colombo, N. / Morice, P. et al. | 2016
- 2004
-
Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscapeOlaussen, K. A. / Postel-Vinay, S. et al. | 2016
- 2017
-
Global trends and predictions in ovarian cancer mortalityMalvezzi, M. / Carioli, G. / Rodriguez, T. / Negri, E. / La Vecchia, C. et al. | 2016
- 2025
-
No ‘cure’ within 12 years of diagnosis among breast cancer patients who are diagnosed via mammographic screening: women diagnosed in the West Midlands region of England 1989–2011Woods, L. M. / Morris, M. / Rachet, B. et al. | 2016
- 2032
-
Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancerJanku, F. / Johnson, L. K. / Karp, D. D. / Atkins, J. T. / Singleton, P. A. / Moss, J. et al. | 2016
- 2039
-
Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study)Aapro, M. / Ludwig, H. / Bokemeyer, C. / Gascón, P. / Boccadoro, M. / Denhaerynck, K. / Krendyukov, A. / Gorray, M. / MacDonald, K. / Abraham, I. et al. | 2016
- 2046
-
Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancerVrdoljak, E. / Marschner, N. / Zielinski, C. / Gligorov, J. / Cortes, J. / Puglisi, F. / Aapro, M. / Fallowfield, L. / Fontana, A. / Inbar, M. et al. | 2016
- 2053
-
Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN studyFurlanetto, J. / Eiermann, W. / Marmé, F. / Reimer, T. / Reinisch, M. / Schmatloch, S. / Stickeler, E. / Thomssen, C. / Untch, M. / Denkert, C. et al. | 2016
- 2059
-
Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY studyVuylsteke, P. / Huizing, M. / Petrakova, K. / Roylance, R. / Laing, R. / Chan, S. / Abell, F. / Gendreau, S. / Rooney, I. / Apt, D. et al. | 2016
- 2067
-
Tumor-related leukocytosis is associated with poor radiation response and clinical outcome in uterine cervical cancer patientsCho, Y. / Kim, K. H. / Yoon, H. I. / Kim, G. E. / Kim, Y. B. et al. | 2016
- 2074
-
Phase III trial comparing 3–6 months of adjuvant FOLFOX4/XELOX in stage II–III colon cancer: safety and compliance in the TOSCA trial†Lonardi, S. / Sobrero, A. / Rosati, G. / Di Bartolomeo, M. / Ronzoni, M. / Aprile, G. / Scartozzi, M. / Banzi, M. / Zampino, M. G. / Pasini, F. et al. | 2016
- 2082
-
Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression†Obermannová, R. / Van Cutsem, E. / Yoshino, T. / Bodoky, G. / Prausová, J. / Garcia-Carbonero, R. / Ciuleanu, T. / Garcia Alfonso, P. / Portnoy, D. / Cohn, A. et al. | 2016
- 2090
-
Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trialIkeda, M. / Shimizu, S. / Sato, T. / Morimoto, M. / Kojima, Y. / Inaba, Y. / Hagihara, A. / Kudo, M. / Nakamori, S. / Kaneko, S. et al. | 2016
- 2097
-
Toward the molecular dissection of peritoneal pseudomyxomaPietrantonio, F. / Perrone, F. / Mennitto, A. / Gleeson, E. M. / Milione, M. / Tamborini, E. / Busico, A. / Settanni, G. / Berenato, R. / Caporale, M. et al. | 2016
- 2103
-
Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trialsYang, J. C. / Sequist, L. V. / Zhou, C. / Schuler, M. / Geater, S. L. / Mok, T. / Hu, C. P. / Yamamoto, N. / Feng, J. / O'Byrne, K. et al. | 2016
- 2111
-
Chromoplectic TPM3–ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinibMansfield, A. S. / Murphy, S. J. / Harris, F. R. / Robinson, S. I. / Marks, R. S. / Johnson, S. H. / Smadbeck, J. B. / Halling, G. C. / Yi, E. S. / Wigle, D. et al. | 2016
- 2117
-
Prognostic value of tumor-infiltrating lymphocytes differs depending on histological type and smoking habit in completely resected non-small-cell lung cancerKinoshita, T. / Muramatsu, R. / Fujita, T. / Nagumo, H. / Sakurai, T. / Noji, S. / Takahata, E. / Yaguchi, T. / Tsukamoto, N. / Kudo-Saito, C. et al. | 2016
- 2124
-
Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody–drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancerLiu, J. F. / Moore, K. N. / Birrer, M. J. / Berlin, S. / Matulonis, U. A. / Infante, J. R. / Wolpin, B. / Poon, K. A. / Firestein, R. / Xu, J. et al. | 2016
- 2131
-
Is the Gleason score the driver for the treatment decision-making of patients with castration-resistant prostate cancer in the new era of the anti-androgenic therapies?Roviello, G. / Generali, D. et al. | 2016
- 2133
-
Reply to the letter to the editor ‘Epstein–Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin, histone deacetylase (HDAC) inhibitors when combined with a proteasome inhibitor are safe and effective in patients with extranodal natural killer/T-cell lymphoma’ by Tan et al.Kim, S. J. / Kim, W. S. et al. | 2016
- 2134
-
Utilisation of the ESMO-MCBS in practice of HTAWild, C. / Grössmann, N. / Bonanno, P. V. / Bucsics, A. / Furst, J. / Garuoliene, K. / Godman, B. / Gulbinovič, J. / Jones, J. / Pomorski, M. K. et al. | 2016
- 2136
-
Reply to the letter to the editor ‘Utilisation of the ESMO-MCBS in practice of HTA’ by Wild et al.Cherny, N. I. / Sullivan, R. / Dafni, U. / Bogaerts, J. / Kerst, J. M. / Zielinski, C. / Piccart, M. J. / de Vries, E. G. et al. | 2016
- 2137
-
Possible determinants of VSL#3 probiotic failure in preventing gastrointestinal adverse events associated with dacomitinib in patients with advanced non-small-cell lung cancer enrolled in ARCHER-1042 trialCeccarelli, G. / Schietroma, I. / Corano Scheri, G. / d'Ettorre, G. / Vullo, V. et al. | 2016
- 2138
-
Reply to the letter to the editor ‘Erroneous conclusions about the association between light alcohol drinking and the risk of cancer: comments on Bagnardi et al.'s meta-analysis, by S.-K. Myung’Bagnardi, V. / Botteri, E. / La Vecchia, C. et al. | 2016
- 2138
-
Erroneous conclusions about the association between light alcohol drinking and the risk of cancer: comments on Bagnardi et al.'s meta-analysisMyung, S. K. et al. | 2016
- 2138
-
reply to the letter to the editor ‘Possible determinants of VSL#3 probiotic failure in preventing gastrointestinal adverse events associated with dacomitinib in patients with advanced non-small-cell lung cancer enrolled in ARCHER-1042 trial’ by Ceccarelli et al.Lacouture, M. E. et al. | 2016
- i1
-
Progress in the treatment of ovarian cancer—lessons from homologous recombination deficiency—the first 10 yearsKaye, S. B. et al. | 2016
- i4
-
Epithelial ovarian cancer: the molecular genetics of epithelial ovarian cancerKrzystyniak, J. / Ceppi, L. / Dizon, D. S. / Birrer, M. J. et al. | 2016
- i11
-
Opportunities in immunotherapy of ovarian cancerCoukos, G. / Tanyi, J. / Kandalaft, L. E. et al. | 2016
- i16
-
The molecular pathology of ovarian serous borderline tumors†Malpica, A. / Wong, K. K. et al. | 2016
- i20
-
Management of borderline ovarian tumorsdu Bois, A. / Trillsch, F. / Mahner, S. / Heitz, F. / Harter, P. et al. | 2016
- i23
-
Molecular imaging in ovarian cancerReyners, A. K. / Broekman, K. E. / Glaudemans, A. W. / Brouwers, A. H. / Arts, H. J. / van der Zee, A. G. / de Vries, E. G. / Jalving, M. et al. | 2016
- i30
-
Neoadjuvant chemotherapy in ovarian cancer revisitedMahner, S. / Trillsch, F. / Chi, D. / Harter, P. / Pfisterer, J. / Hilpert, F. / Burges, A. / Weissenbacher, T. / du Bois, A. et al. | 2016
- i33
-
Anti-angiogenic agents in ovarian cancer: past, present, and futureMonk, B. J. / Minion, L. E. / Coleman, R. L. et al. | 2016
- i40
-
PARP inhibitors in ovarian cancerLedermann, J. A. et al. | 2016
- i45
-
Low-grade serous carcinoma of the ovary or peritoneumGershenson, D. M. et al. | 2016
- i50
-
Clear-cell carcinoma of the ovaryFujiwara, K. / Shintani, D. / Nishikawa, T. et al. | 2016
- i53
-
Mucinous epithelial ovarian carcinomaPerren, T. J. et al. | 2016
- i58
-
Optimal primary therapy of ovarian cancerBookman, M. A. et al. | 2016
- i63
-
Recurrent ovarian cancerPujade-Lauraine, E. / Combe, P. et al. | 2016
- i66
-
Patient-reported outcomes (PRO) in ovarian cancer clinical trials—lost opportunities and lessons learnedFriedlander, M. / Mercieca-Bebber, R. L. / King, M. T. et al. | 2016
- i72
-
Advanced ovarian cancer: 20 years of ovarian cancer treatmentPoveda, A. / Romero, I. et al. | 2016
- ii1
-
P-004 Immunohistochemical Expression of LRG5 and CD44 in Colorectal Polyps and Adenocarcinomas: Implications for CarcinogenesisYildiz, D. / Balci, M. / Yildiz, S. et al. | 2016
- ii1
-
P-002 Suppression of lipocalin-2 promotes the epithelial-to-mesenchymal transition in human colorectal cancer cellsKim, S. L. / Kim, S. W. / Park, Y. R. et al. | 2016
- ii1
-
P-003 Extended Mutational Profiling for Metastatic Colorectal Cancer (CRC): beyond RAS Molecular Spectrum of KRAS-NRAS-BRAF and PI3K in Cancer ColorectalOtero, S. / Saldias, P. / Sanchez, M. / Colica, M. / Bramuglia, G. / Jankilevich, G. et al. | 2016
- ii1
-
P-001 Jointly alterations of voltage-gated Na+ channel SCN5A and E-cadherin genes may impact tumor cell proliferation in human colorectal cancerTuncel, H. / Shimamto, F. / Erdamar, S. / Korpinar, M. A. et al. | 2016
- ii2
-
P-007 Comparison of methods for measuring total cell-free DNA and KRAS mutations in plasma from metastatic colorectal cancer patientsDemuth, C. / Spindler, K. L. / Johansen, J. S. / Pallisgaard, N. / Nielsen, D. / Hoegdall, E. / Vittrup, B. / Sørensen, B. et al. | 2016
- ii2
-
P-006 Hypermethylation of APC, CDH13, MLH1, MGMT, P16 and RASSF1A promoter regions in patients with colorectal cancerKit, O. / Vodolazhsky, D. / Timoshkina, N. / Vladimirova, L. / Dvadnenko, K. / Kutilin, D. et al. | 2016
- ii2
-
P-005 Prognostic significance of the frequency of primary cilia in cells of small bowel and colorectal adenocarcinomaKupec, M. / Dvorak, J. / Hadzi Nikolov, D. / Dusek, L. / Filipova, A. / Richter, I. / Buka, D. / Ryska, A. / Mokry, J. / Filip, S. et al. | 2016
- ii3
-
P-008 Plasma lipidome of patients with advanced colorectal cancerFigueiredo, A. / Serafim, P. / Azzolini, A. / lo Turco, E. / Silva, I. / Forones, N. et al. | 2016
- ii3
-
P-010 Next generation sequencing mutational analysis of primary and metastatic colorectal cancer samples in relationship to efficacy of cetuximab-based therapyNemecek, R. / Berkovcova, J. / Slaby, O. / Svoboda, M. et al. | 2016
- ii3
-
P-009 Inhibition of Gastrointestinal Neuroendocrine Tumor by A New Marker of Normal Neuroendocrine CellsPan, B. / Zhang, T. / Zhao, C. / Liu, Y. / Guo, Y. et al. | 2016
- ii3
-
P-011 Tumor budding is associated with low expression of miRNA-148a and miRNA-625-3p in colorectal cancerBaltruskeviciene, E. / Schveigert, D. / Mickys, U. / Suziedelis, K. / Aleknavicius, E. et al. | 2016
- ii4
-
P-013 Prognostic significance of cyclin D1 and p21 (WAF1/CIP1) in Gastric CancerMichalaki, V. / Theodosopoulos, T. / Dafnios, N. / Vezakis, A. / Karvouni, E. / Papadimitriou, C. et al. | 2016
- ii4
-
P-014 Are RHOA, CSNK1A1, DVL2, FZD8 and LRP5 Genes Novel Biomarkers in the conversion from Intestinal Metaplasia to Gastric Cancer?Demirci, U. / Örenay Boyacıoğlu, S. / Kasap, E. / Bilgiç, F. / Gerçeker, E. / Yıldırım, H. / Baykan, A. / Ellidokuz, E. / Yüceyar, M. / Korkmaz, M. et al. | 2016
- ii4
-
P-012 CCL2 expression is correlated with Snail expression and affects the prognosis of patients with gastric cancerZhang, J. / Yan, Y. / Wang, J. et al. | 2016
- ii5
-
P-015 Detection of gene сopy number variation as predictive markers for metastases in patients with gastric cancerKit, O. / Kutilin, D. / Vodolazhsky, D. / Tatimov, M. / Maslov, A. / Vladimirova, L. et al. | 2016
- ii5
-
P-017 Analysis of microRNA expression in Gastroenteropancreatic Neuroendocrine TumorVega Neira, S. J. / Torres Carvajal, M. M. / Barrera Herrera, L. / Andrade Perez, R. / Lopez Panqueva, R. et al. | 2016
- ii5
-
P-016 Circulating mRNA expression of CD133, SNAIL, ZEB1 and ZHX as biomarkers in gastric and esophageal cancerLongo Muñoz, F. / Earl, J. / Martinez Avila, J. / Rodriguez Garrote, M. / Guerrero, C. / Galindo, J. / Priego, P. / Rodriguez, G. / García-Moreno, F. / Lopez, F. et al. | 2016
- ii6
-
P-020 Targeting multidrug resistance – associated protein 4 (MRP4/ABCC4) in pancreatic cancerMay, M. / Alejandro, C. / Gomez, N. / Diez, F. / Copsel, S. / Iturbe, J. / Mohr, N. / Fernandez, N. / Shayo, C. / Davio, C. et al. | 2016
- ii6
-
P-018 Assessment of therapeutic potential of arsenic trioxide in the management of human hepatocellular carcinomaDugo, E. / Yedjou, C. / Stevens, J. / Tchounwou, P. et al. | 2016
- ii6
-
P-019 Use of serum levels of cytokine TGF β1 in detection of Hepatocellular carcinoma in patients with chronic liver diseaseMehmedovic, A. / Prnjavorac, B. / Vukobrat- Bijedić, Z. et al. | 2016
- ii7
-
P-021 Tanshinone IIA can inhibit human pancreatic carcinoma BxPC3 cells through decreasing the protein expressions of IGFR, EGFR, VEGFR and blocking both Ras/Raf/MEK/ERK and Ras/PI3K/AKT/mTOR pathway in vitro and in vivoSu, C. C. et al. | 2016
- ii7
-
P-024 Carcinoembryonic antigen (CEA) and the carcinoma antigen 19-9 (CA 19-9) together in early diagnosis of Stage I-II colorectal adenocarcinoma. A case-control studyLumachi, F. / Chiara, G. / Tozzoli, R. / Lo Re, G. / Basso, S. et al. | 2016
- ii7
-
P-022 Predictive biomarkers of pathologic response to preoperative chemoradiotherapy in locally advanced rectal cancerJankovic, R. / Stojanovic-Rundic, S. / Micev, M. / Krivokapic, Z. / Nikolić, V. / Popov, I. / Gavrilovic, D. / Plesinac-Karapandzic, V. / Djuric-Stefanovic, A. / Radulovic, S. et al. | 2016
- ii8
-
P-027 Cancer stem cells marker CD44 and Notch activation predict unfavorable prognosis in metastatic colon cancer patients treated with anti VEGF-therapyNegri, F. V. / Bozzetti, C. / Azzoni, C. / Bottarelli, L. / Squadrilli, A. / Pedrazzi, G. / Lagrasta, C. / Tamagnini, I. / Bisagni, A. / Porzio, R. et al. | 2016
- ii8
-
P-025 Prognostic markers to predict efficacy of 5-FU rechallenge as third line chemotherapy in metastatic colorectal cancerChung, I. J. / Kim, K. / Shim, H. J. / Hwang, J. E. / Bae, W. K. / Cho, S. H. et al. | 2016
- ii8
-
P-026 Assessment of lymph nodes for micrometastasis in high risk patients with colorectal cancerBotiralieva, G. / Nishanov, D. / Navruzov, S. et al. | 2016
- ii9
-
P-029 Prognostic analysis of colon cancer patients using elastic lamina invasion and ascitic CEALee, I. K. / Lee, Y. S. / Oh, S. T. et al. | 2016
- ii9
-
P-030 Tumor-infiltrating lymphocytes (TILs) density as prognostic determinant in stage II colorectal cancerRicci, V. / Comino, A. / Vivenza, D. / Granetto, C. / Lo Nigro, C. / Ferrero, M. / Merlano, M. C. et al. | 2016
- ii9
-
P-028 Analysis of KRAS and NRAS mutations in Greek patients with metastatic Colorectal Cancer (mCRC) on the registry of the Gastro-intestinal Cancer Study Group (GIC-SG)Souglakos, J. / Saridaki, Z. / Gouges, N. / Voutsina, A. / Tzardi, M. / Kalikaki, A. / Sfakianaki, M. / Athanasiadis, A. / Xynos, E. / Boukovinas, I. et al. | 2016
- ii9
-
P-032 A complete blood count as a prognostic marker in patients with metastatic colorectal cancer (mCRC)Krakowska, M. / Debska-Szmich, S. / Czernek, U. / Czyzykowski, R. / Potemski, P. et al. | 2016
- ii10
-
P-033 Metabolic analysis of advanced Colorectal Cancer Tissues Using Two-Dimensional NMR SpectroscopyKim, S. / Baek, I. K. / Cho, Y. K. et al. | 2016
- ii10
-
P-034 The potential of extravasated platelet aggregation as a surrogate marker for overall survival in patients with advanced gastric cancer treated by preoperative docetaxel, cisplatin, and S-1Fushida, S. / Saito, H. / Kurata, T. / Kinoshita, J. / Oyama, K. / Miyashita, T. / Ohta, T. et al. | 2016
- ii10
-
P-035 Simultaneous carcinoembryonic antigen (CEA), carcinoma antigen 19-9 (CA 19-9) and 125 (CA-125) measurement in patients with gastric cancer (stage IA-IB): a case-control studyLumachi, F. / Chiara, G. / Tozzoli, R. / Lo Re, G. / Basso, S. et al. | 2016
- ii11
-
P-036 Long Interspersed Nuclear Element (LINE)-1 Methylation Level as a Molecular Marker of Early Gastric CancerChung, W. C. / Choi, S. A. et al. | 2016
- ii11
-
P-037 The role of carcino-embryonic antigen testing among western patients with resected gastric cancerGreenleaf, E. / Hollenbeak, C. / Wong, J. / Mirkin, K. A. et al. | 2016
- ii11
-
P-038 MET activation via exon 14 skipping mutations (METex14del): gastrointestinal prevalence and sensitivity to MET inhibitor AMG337Cecchi, F. / Rabizadeh, S. / Weingarten, P. / Tsai, C. / Zhou, L. / Hembrough, T. et al. | 2016
- ii12
-
P-041 IKAROS: a potential prognostic marker in pancreatic ductal adenocarcinomaCruz Ramos, M. / Rodriguez-Remirez, M. / Minguez, P. / Cebrian, A. / del Puerto-Nevado, L. / Celdran, A. / Garcia-Foncillas Lopez, J. et al. | 2016
- ii12
-
P-039 5-Fluorouracil Degradation Rate in Patients with Recurrent Gastrointestinal Cancer Treated with Metronomic CapecitabineRoberto, M. / Romiti, A. / Lionetto, L. / D'Antonio, C. / Onesti, C. / Botticelli, A. / Milano, A. / Falcone, R. / Occhipinti, M. / Mazzuca, F. et al. | 2016
- ii12
-
P-040 Dihydropyrimidine Dehydrogenase (DPD) and Thymidylate Synthase (TYMS) Germline Pharmacogenomics Role in Predicting Fluoropyrimidines Toxicity in Patients with Gastrointestinal (GI) MalignanciesKhushman, M. / Hosein, P. / Cameron, D. / Clarkson, D. / Butler, T. / Vu, M. / Norden, C. / Baliem, W. / Jones, V. / Bhadkamkar, S. et al. | 2016
- ii13
-
P-044 Primary anorectal melanomas: rare entity, interest of targeting CKITOualla, K. / Amarti, A. / El Mesbahi, O. / Mellas, N. / Tizniti, S. et al. | 2016
- ii13
-
P-043 Significance of bcl-2 in rectal cancer recurrencesBotiralieva, G. / Navruzov, S. / Nishanov, D. / Shomansurova, N. et al. | 2016
- ii13
-
P-045 Resistant form of helicobacter pylori in development of stomach MALT lymphomaMallaev, M. / Yusupbekov, A. et al. | 2016
- ii13
-
P-042 The genetic profile of pancreatic circulating tumor cellsApostolou, P. / Toloudi, M. / Papasotiriou, I. et al. | 2016
- ii14
-
P-048 Prognostic Impact of CA19-9 Level at Diagnosis in Resected Stage I-III Pancreatic Adenocarcinoma: a US Population StudyMirkin, K. / Hollenbeak, C. / Wong, J. et al. | 2016
- ii14
-
P-047 Effectiveness of TACE as bridge therapy for liver transplant in hepatocellular carcinomaRibeiro, C. / Barreira, J. / Parmanande, A. / Semedo, P. / Semedo, M. / Silva, M. / Costa, N. / Ribeiro, V. / Coimbra, E. / Barroso, E. et al. | 2016
- ii14
-
P-046 Low-dose paclitaxel suppresses the induction of M2 macrophages in gastric cancerYamaguchi, T. / Fushida, S. / Ohta, T. et al. | 2016
- ii15
-
P-049 A population study of correlation between the treatment rate for monoclonal antibodies (Mabs) and mortality rate in patients with metastatic colorectal cancer (mCRC) in RussiaFedyanin, M. / Polyanskaya, E. / Sekhina, O. / Tryakin, A. / Tjulandin, S. et al. | 2016
- ii15
-
P-050 The pharmacological costs of first-line therapies in unselected advanced colorectal cancer patients: a review of published phase III trialsGiuliani, J. / Bonetti, A. et al. | 2016
- ii15
-
P-051 Preliminary clinical and pathologic characteristics of patients treated in second-line (2L) with 25 cycles (Cy) or more of FOLFIRI + Aflibercept (FA)Pericay, C. / Martínez-Lago, N. / Corral, M. / Macías Declara, I. / Donnay, O. / Juez Martel, I. / García-Paredes, B. / Méndez Méndez, J. C. / Cacho Lanvin, D. / González-Astorga, B. et al. | 2016
- ii16
-
P-054 The clinical predictor of antitumor efficacy of cetuximab based regimen in first-line therapy to unresectable metastatic colorectal cancerTanioka, H. / Nagasaka, T. / Asano, M. / Ikeda, K. / Yoshida, R. / Waki, N. / Ishizaki, M. / Yamashita, K. et al. | 2016
- ii16
-
P-052 Phase II study of biweekly cetuximab and irinotecan as third-line therapy in patients with pre-treated KRAS exon2 wild-type metastatic colorectal cancerOsumi, H. / Shinozaki, E. / Suenaga, M. / Matsusaka, S. / Nakayama, I. / Wakatsuki, T. / Ogura, M. / Ozaka, M. / Takashi, I. / Takahari, D. et al. | 2016
- ii16
-
P-053 Updated analysis of induction & maintenance adjuvant chemotherapy with 3-month oxaliplatin-based regimen followed by 3 months capecitabine in patients with stage III and high-risk stage II colorectal cancer :(JSWOG C2)Tanioka, H. / Yamashita, K. / Tsuruta, A. / Tsuji, A. / Nagasaka, T. / Okumura, H. / Oka, Y. / Inukai, M. / Yamakawa, T. / Yamatsuji, T. et al. | 2016
- ii17
-
P-055 Prospective evaluation for chemotherapy-induced nausea and vomiting in colorectal cancer receiving oxaliplatin-based chemotherapy of moderate emetic riskShimokawa, M. / Hayashi, T. / Kogawa, T. / Matsui, R. / Suzuki, K. / Saeki, T. / Aiba, K. / Tamura, K. et al. | 2016
- ii17
-
P-057 Body Composition (BC), beyond Body Mass Index (BMI) and sarcopenia, has a major prognostic impact on patients with refractory advanced Colorectal Cancer (aCRC)Van Bogaert, C. / Vandeputte, C. / Ameye, L. / Paesmans, M. / Guiot, T. / Deleporte, A. / Charette, N. / Hendlisz, A. et al. | 2016
- ii17
-
P-056 Outcome of maintenance therapy in patients who achieved NED after liver resection for mCRCAl-Hajeili, M. / Serzan, M. / Prins, P. / Marshall, J. et al. | 2016
- ii18
-
P-060 Endoscopic colorectal stenting for malignant large bowel obstruction comparing to surgeryKang, D. H. / Kim, H. W. / Choi, C. W. / Park, S. B. / Kim, S. J. / Nam, H. S. / Jang, H. H. / Lee, S. B. / Lee, S. H. / Park, J. M. et al. | 2016
- ii18
-
P-058 Nutritional status and survival in elderly patients with colorectal cancerBarao, K. / Fucuta, P. / Vicente, M. / Forones, N. et al. | 2016
- ii18
-
P-059 Phase I trial of FOLFOXIRI in combination with Panitumumab as first-line treatment of RAS wild-type metastatic colorectal cancer (JACCRO CC-14)Tsuji, A. / Nakamura, M. / Ogawa, M. / Satake, H. / Kotake, T. / Hatachi, Y. / Takagane, A. / Okita, Y. / Nakamura, K. / Onikubo, T. et al. | 2016
- ii19
-
P-061 Real-world experiences of use of aflibercept in patients with stage IV colorectal cancer in the North-West of EnglandFlaum, N. / Kurup, R. / Tong, D. / Alchawaf, A. / Lau, S. / Harle, A. / Hajri, R. / Williamson, D. / Papaxoinos, G. / Mullamitha, S. et al. | 2016
- ii19
-
P-062 Correlation of histological Tumor Regression Grading (TRG) with radiological response and long-term outcome after preoperative chemotherapy for Colorectal Liver Metastases: a propensity score matching analysisInada, R. / Murotani, K. / Iwamoto, S. / Kaibori, M. / Ishizaki, M. / Iida, H. / Matsui, K. / Oishi, M. / Mastumoto, T. / Michiura, T. et al. | 2016
- ii19
-
P-063 Effect of age on treatment effect and tolerability of SIRT when added to mFOLFOX chemotherapy in patients with metastatic colorectal cancer (mCRC) – results from the SIRFLOX studyvan Hazel, G. / Heinemann, V. / Sharma, N. / Findlay, M. / Ricke, J. / Peeters, M. / Gebski, V. / Van Buskirk, M. / Gibbs, P. et al. | 2016
- ii20
-
P-066 New methods of detecting oxaliplatin-induced peripheral sensory neuropathy in patients undergoing adjuvant treatment with 5-fluorouracil and oxaliplatin for colon cancerSzpejewska, J. / Mørch, C. D. / Yilmaz, M. / Arendt-Nielsen, L. / Falkmer, U. et al. | 2016
- ii20
-
P-065 Surveillance colonoscopy after endoscopic resection of early colon cancerKim, J. O. / Jeon, S. R. / Kim, H. G. / Lee, J. S. et al. | 2016
- ii20
-
P-064 Bevacizumab with chemodoublet as conversion-to-resectability therapy for patients with liver metastases of colorectal cancerRistic, M. / Stanic, N. / Radosavljevic, D. / Ristic, D. / Spasic, J. et al. | 2016
- ii21
-
P-069 Neoadjuvant chemotherapy for esophageal cancer: comparison of DCS (DTX/CDDP/S-1) chemotherapy with FAN (5-FU/ADM/Nedaplatin) chemotherapyShimoji, H. / Nishimaki, T. / Karimata, H. / Hayasaka, K. et al. | 2016
- ii21
-
P-070 The risk of thromboembolic events in upper GI cancer patients undergoing preoperative chemotherapyMohan Annet Jesmine, M. / Papavasileiou, V. / Chatzigeorgiou, V. / Kamposioras, K. et al. | 2016
- ii21
-
P-068 Cetuximab in addition to oxaliplatin, fluorouracil and radiotherapy for patients with esophageal cancer treated without surgeryAlexandersson von Döbeln, G. / Wagenius, G. / Holtved, E. / Hjortland Geir, O. / Nilsson, M. / Baeksgaard, L. et al. | 2016